company_description
stringlengths 59
1.56k
| company_website
stringlengths 7
88
⌀ | private_or_public
stringclasses 2
values | slogan
stringlengths 4
172
⌀ | location
stringlengths 5
74
⌀ | found_in_year
float64 1.85k
2.02k
⌀ | investors
stringlengths 2
177
⌀ | company_status
stringclasses 5
values | company_products_or_services
stringlengths 47
1.41k
| problem_being_solved
stringlengths 17
663
⌀ | solution_offered
stringlengths 24
418
⌀ | value_proposition_x
stringlengths 17
403
| business_model
stringlengths 9
998
⌀ | technology_used
stringlengths 68
941
⌀ | executive_summary
stringlengths 217
2.33k
⌀ | filename
stringlengths 89
159
| category
stringclasses 6
values | revenue
float64 0.04
1.5M
⌀ | funding_amount
float64 0.13
3.8M
⌀ | funding_round
stringlengths 1
119
⌀ | market_cap
stringlengths 3
92
⌀ | stock_symbol_and_price
stringlengths 3
104
⌀ | operating_margin
stringlengths 3
81
⌀ | pe_ratio_or_margin
stringclasses 20
values | leadership
int64 -1
5
| capital_and_financial_mgmt
int64 -1
5
| differentiation
int64 -1
5
| business_model_and_channel
int64 -1
5
| marketing
int64 -1
5
| company_culture
int64 -1
5
| resilience_and_pivots
int64 -1
5
| fulfilling_customer_needs
int64 -1
5
| laws_regulations_ip
int64 -1
5
| value_proposition_y
int64 -1
5
| timing
int64 -1
5
| product_design_and_idea
int64 -1
5
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
R3 is the developer of an enterprise blockchain software intended to offer distributed ledger technology for the financial services industry. Their protocol hosts applications for banks, clearinghouses, exchanges, market infrastructure providers, asset managers, and central banks among others, enabling financial and legal experts to manage and execute institutions' financial agreements in synchrony with their peers.
R3's mission is to create open, trusted, and advanced digital economies. The company's blockchain technology is used to improve financial markets, including banking, insurance, capital markets, and global trade. | https://r3.com/ | Private | Enabling an open, trusted, and advanced digital economy | NY, New York | 2,014 | Venture Capital - Backed
B3(Brazil), Bangkok Bank, Bank Bradesco, Barclays, and BBVA USA Bancshares are 5 of 60 investors who have invested in R3. | Growth | Founded in 2014, R3 quickly became a leader in developing digital solutions for businesses worldwide, notably through the many applications of its distributed ledger technology, Corda, in tokenization and financial markets operations.
Specializing in digital markets, R3’s Corda, digital assets, digital currencies, and interoperability solutions enable transactions with control, security, and privacy, providing asset mobility in a permissioned, trusted environment.
By continuously striving for innovative solutions, R3 continues to shape and progress digital economies. | Digital solutions through their ledger technology, Corda, in tokenization and financial markets operations. | R3's focus on digital markets enables transactions at higher security that provides asset mobility in a trusted environment. | In your own words | n/a private company | R3's Corda is powering the digitalization of assets and currencies connecting global markets; it is the first digital bond issuance on Euroclear's Digital Financial Market Infrastructure.
The use of Corda’s unique distributed architecture demonstrates the capabilities of the platform to support the issuance and primary distribution part of the lifecycle of a bond under the existing legal framework applicable to an ICSD. R3 is enabling an open, trusted and enduring digital economy where value is securely exchanged. | “R3 has achieved success by promoting collaboration among banks as they delve into blockchain technology,” stated Richard Johnson, vice president of market structure & technology at Greenwich Associates. “They have engaged with numerous blockchain technology firms.”
R3CEV is primarily recognized for its homegrown Corda blockchain platform, which Richard Brown, CTO of R3CEV, described in the consortium’s blog as being “specifically crafted to handle financial agreements between regulated financial entities.” He added, “It draws significant inspiration from blockchain systems, capturing their advantages while avoiding the design choices that can render blockchains unsuitable for many banking applications.” | /content/drive/MyDrive/engin183profiles/Blockchain Profile/xuchristine_5617342_91210646_Spring2025_BusinessProfileFormat_Christine Xu.docx | Blockchain Profile | 115.4 | 122 | null | null | null | null | null | 3 | 4 | 3 | -1 | 4 | 3 | 5 | 4 | 4 | 4 | 4 | 3 |
Bybit is a professional cryptocurrency exchange platform. Their purpose is to become the most dependable crypto trading service through security, transparency, and reliability. They aim to promote a diverse and healthy environment of crypto education and growth opportunities. | www.bybit.com | Private | “Listen, care and improve” | Central Region, Singapore | 2,018 | 9 institutional investors including Streamlined Ventures, Hack VC and DRAGONFLY. | Growth | Bybit offers a 24/7 multilingual customer service with options for spot and derivatives trading. Also offer mining and staking products as well as API support for algorithmic trading. | Steep learning curve, crypto security, risk management features | Intuitive and accessible platform, cold storage, 2FA, strong data encryption, take-profit & stop-loss orders | Providing a widely useful, secure, and user-friendly platform for crypto trading | Primarily transaction model. Also referrals and partnerships. Leverage / Liquidation fees. | High frequency trading engine + low latency technology to provide a very fast trading experience even during peak times. This helps for highly volatile cryptocurrency trading as well. Cloud infrastructure (AWS) for reliability. Advanced security protocols. | Bybit was a success due to several key factors such as contextual timing, and unique and desirable product design through differentiation from competitors in the blockchain industry. Founded in early 2018 during the bitcoin bubble crash from 2017-2018, the company capitalized on the sudden influx of new users seeking to invest in the comparatively low price on cryptocurrencies. The company’s inherently UI friendly platform design coupled with vast advanced trading tool options brought in an enormous number of new users while also maintaining and nurturing advanced traders. | /content/drive/MyDrive/engin183profiles/Blockchain Profile/yidabin_5202061_91210031_Bybit Business Profile SP2025.docx | Blockchain Profile | 269.5 | null | null | N/A | N/A (Not publicly traded) | null | null | 3 | 4 | 5 | 4 | 4 | 2 | 4 | 5 | 4 | 5 | 5 | 5 |
MoonPay is a financial technology company that builds payments infrastructure for crypto. Our on-and-off-ramp suite of products provides a seamless experience for converting between fiat currencies and cryptocurrencies using all major payment methods including debit and credit card, local bank transfers, Apple Pay and Google Pay. | https://www.moonpay.com/ | Private | A whole world of crypto, in one simple account | Miami, USA | 2,019 | Tiger Global Management, Coatue Management, Blossom Capital, New Enterprise Associates, Paradigm, and Thrive Capital. | Growth | MoonPay's core product is an on-ramp and off-ramp solution, allowing users to buy, sell, and swap cryptocurrencies using credit/debit cards, bank transfers, Apple Pay, Google Pay, and PayPal. MoonPay also provides HyperMint, which is an NFT minting platform for brands and creators, and MoonPay Concierge - a premium service for high-net-worth individuals to purchase high-value digital assets. The company partners with crypto exchanges, wallets, and NFT platforms, integrating its payment infrastructure to streamline Web3 adoption. | MoonPay solves the problem of complex and inaccessible crypto transactions. By bridging traditional finance with Web3, MoonPay lowers entry barriers for mainstream adoption of cryptocurrencies and NFTs. | Providing a seamless, user-friendly payment infrastructure that allows anyone to buy, sell, and swap cryptocurrencies using familiar payment methods like credit cards, bank transfers, and digital wallets. | MoonPay’s value proposition lies in its ability to provide a fast, secure, and user-friendly gateway between traditional finance and the crypto economy. | MoonPay makes money by charging fees on crypto transactions, like when people buy, sell, or swap cryptocurrencies through its platform. It works with exchanges, wallets, and NFT marketplaces to provide an easy way for users to convert regular money into crypto. MoonPay also offers extra services like HyperMint, which helps businesses create NFTs, and MoonPay Concierge, a service for wealthy individuals who want to buy expensive digital assets. Overall, its business model is based on making crypto more accessible while earning revenue from transaction fees and premium services. | Moonpay definitely uses the blockchain and cryptographic protocols to ensure the safety of their transactions. They probably use some type of API integration to connect with other platforms and access wallets. In terms of their tech stack, they use Node.js, React, TypeScript, CloudFlare, Redis, Amazon S3, GraphQL, ExpressJS, Heroku, Amazon RDS, Tailwind CSS, Apollo, Postman Amazon SES, and Netlify. | I believe that Moonpay was a success due to multiple factors that I've ranked. First, the timing of this company is basically impeccable. The crypto and blockchain market is thriving and continues to hyperexpand, alongside this expansion is the interest of the general crowd. People who have no knowledge of the crypto space are easily able to access this space through moonpay. Furthermore, I think the company culture is very outstanding, since they follow this acronym "B.L.O.C.K" which gives them a plus rating in terms of culture. Additionally, their product design and idea follow a very modern aesthetic, which appeals more specifically to their target audience. And obviously, their business model, which makes money from charging each transaction is just a wonderful money-making model itself in the finance space, allowing for rapid growth and financial surplus. | /content/drive/MyDrive/engin183profiles/Blockchain Profile/yudavid_5621219_91203820_Spring2025_BusinessProfileFormat.docx | Blockchain Profile | null | 555 | Series A Financing Round | null | null | null | null | 3 | 5 | 3 | 2 | 3 | 5 | 3 | 5 | 5 | 4 | 5 | 5 |
IdentifyHer is a Dublin-based digital health startup founded in 2021. The company specializes in creating innovative technology solutions to support women experiencing perimenopause and menopause. Their flagship product, Peri, is a wearable biosensor that tracks physiological symptoms using AI and data analytics, providing both users and clinicians with actionable health insights. | https://www.identifyher.ai | Private | Empowering Women’s Midlife Health | Dublin, Ireland | 2,021 | Early-stage VCs and grant support | Growth | IdentifyHer’s flagship product, Peri, is a wearable device that tracks symptoms such as hot flashes, night sweats, and anxiety. It uses advanced biosensors and AI to provide real-time, personalized health insights to women and healthcare providers. This allows for proactive care and tailored treatment during the perimenopausal phase. | Millions of women experience perimenopausal symptoms but lack objective ways to track and manage them. | IdentifyHer’s Peri device collects real-time physiological data and uses AI to generate insights. | By combining biosensing and AI, IdentifyHer bridges a gap in women’s healthcare with accurate, actionable, and personalized care. | IdentifyHer operates on a B2B2C model, offering its wearable device through partnerships with healthcare providers and clinics, as well as direct-to-consumer sales via online channels. | Peri leverages wearable biosensor technology integrated with AI-powered analytics. The device continuously tracks key symptoms and offers tailored health recommendations through a connected mobile application. | IdentifyHer is a trailblazing health tech startup tackling an underserved segment in women’s health perimenopause. Their innovative product, Peri, combines biosensor technology and AI to deliver real-time, personalized insights for symptom tracking and management. With a solid founding team, an unmet market need, and a thoughtful go-to-market strategy, IdentifyHer is well-positioned to make a meaningful impact in digital health. While clinical validation and long-term scalability remain in progress, the company’s clear value proposition and early traction suggest a bright future. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/aryansimon_5727271_91338141_Spring2025_IdentifyHerPeri.docx | Healthcare Profile | null | 0.722 | Seed/VC-backed | null | null | null | null | 4 | 3 | 4 | 4 | -1 | 4 | 4 | -1 | -1 | 5 | 4 | 5 |
Ferrum Health is a San Francisco-based AI healthcare startup founded in 2017. The company was built with a mission to reduce preventable medical errors in healthcare by enabling safe, private, and scalable deployment of artificial intelligence in clinical workflows. Rather than building its own AI models, Ferrum provides hospitals and healthcare systems with a secure infrastructure to manage and evaluate third-party AI tools. Its core purpose is to empower healthcare providers with trustworthy, explainable AI tools while ensuring compliance, data privacy, and minimal IT burden. Ferrum Health is one of the few startups focused on the often overlooked but critical area of AI governance and safety, helping health systems avoid unnecessary risks. | https://ferrumhealth.com | Private | AI Patient Safety Platform | San Francisco, CA | 2,017 | 9M+ from Urban Innovation Fund, Founders Fund, and others | Growth | Ferrum Health offers a turnkey AI platform for health systems to evaluate, monitor, and operationalize AI tools, especially in radiology. Their flagship product is a private, on-premise AI hub that enables hospitals to run vetted AI models for cancer detection, diagnostic enhancement, and clinical reporting—without needing to send patient data to the cloud. Their services also include AI governance, deployment infrastructure, performance tracking, and bias audits to ensure health systems can adopt AI tools safely and ethically. | Most hospitals lack the infrastructure and expertise to safely deploy AI, and existing cloud-based solutions pose data privacy risks. There’s also no simple way to validate or monitor third-party models once implemented. | Ferrum Health provides a secure platform to evaluate, govern, and deploy AI models inside a hospital’s firewall. It minimizes risk while enabling AI innovation in diagnostics and clinical workflows. | Ferrum helps hospitals improve patient outcomes using AI—without compromising on safety, privacy, or regulatory compliance. | Ferrum operates a subscription-based B2B SaaS model, licensing its AI platform to hospital networks. Contracts are typically multi-year with pricing based on deployment scale and number of AI models used. | Ferrum’s platform is built with a containerized, on-premise architecture allowing plug-and-play deployment of AI models. It integrates with hospital PACS systems and EHRs, with capabilities for continuous performance monitoring, security auditing, and feedback loops. Technologies include Docker, Kubernetes, Python, AI model interpreters, and custom analytics dashboards. | Ferrum Health stands out in the AI healthcare landscape by addressing a crucial but often neglected aspect: safe and ethical AI deployment. While other startups focus on flashy AI diagnostics, Ferrum builds the infrastructure that makes AI actually usable and trustworthy in clinical settings. Their platform's emphasis on data privacy, model auditability, and patient safety has made it a valuable partner for hospitals trying to adopt AI without legal or ethical risk. With a strong leadership team, growing traction, and a mission that resonates with modern healthcare needs, Ferrum Health is well-positioned to become the backbone of enterprise-grade AI in medicine. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/bashirosaydasif_LATE_5670978_91341707_Spring2025_BusinessProfileFormat-2.docx | Healthcare Profile | 3.2 | 31 | Seed and Series A | null | null | null | null | 5 | 4 | 5 | 5 | 2 | 4 | 4 | 4 | 4 | 5 | 4 | 4 |
GeneDx is a biotechnology company specializing in genetic testing services, with a primary focus on rare and ultra-rare disorders. Founded in 2000 by Sherri Bale and John Compton, former scientists from the National Institutes of Health (NIH), the company was established to provide clinical diagnostic services for conditions lacking commercial testing options at the time. GeneDx aims to deliver personalized and actionable health insights that inform diagnosis, direct treatment, and improve drug discovery. | https://www.genedx.com | Public | One test. Big picture. Brighter futures. | Stamford, Connecticut, USA | 2,020 | Bain Capital Life Sciences, Accelmed Partners, Veritas Capital | Growth | GeneDx offers a comprehensive suite of genetic testing services, including: Exome Sequencing: XomeDx® delivers higher diagnostic yield compared to chromosomal microarray (CMA) and multigene panels. Genome Sequencing: GenomeSeqDx is the most comprehensive genetic test available, including mitochondrial genome sequencing. Rapid Genome Sequencing: GenomeXpress® assists in identifying genetic disorders in infants in intensive care units. | Many patients with rare and ultra-rare genetic disorders face prolonged diagnostic odysseys, leading to delays in appropriate treatment and management. | GeneDx provides advanced genetic testing services, such as exome and genome sequencing, to deliver accurate and timely diagnoses for individuals with rare genetic conditions. | By leveraging cutting-edge genomic technologies and extensive clinical expertise, GeneDx empowers healthcare providers and patients with actionable insights, facilitating personalized medical care and improving health outcomes. | GeneDx operates on a fixed-price model for its genetic testing services, offering transparent pricing for healthcare providers and patients. The company also collaborates with biopharmaceutical partners and engages in research initiatives to advance genomic medicine. | GeneDx utilizes next-generation sequencing technologies, including whole exome and whole genome sequencing, to analyze genetic material. The company employs artificial intelligence and machine learning algorithms to interpret complex genomic data, enhancing diagnostic accuracy and efficiency. | GeneDx is a biotechnology company that specializes in genetic testing for rare and ultra-rare disorders, founded in 2000. The company uses cutting-edge technologies, including whole exome and genome sequencing, to provide accurate diagnostics that aid in the treatment of patients with complex genetic conditions. GeneDx aims to enhance patient outcomes by offering comprehensive genetic testing solutions, which are crucial for early detection and personalized treatment strategies. The company's services extend to newborn screening, critical care diagnostics, and collaboration with biopharmaceutical companies, supporting the development of precision medicine. GeneDx is also advancing AI-powered analytics to improve the efficiency and accuracy of genetic test interpretations, making it a leader in the rapidly growing genomics industry. Its innovative approach allows for better identification of rare genetic disorders and contributes to the growing field of genomic medicine. With strong financial growth and a solid market position, GeneDx continues to innovate and expand its offerings. The company is well-poised for further growth, particularly in the areas of newborn screening and AI-driven genetic diagnostics. However, it must navigate the competitive landscape and regulatory challenges to maintain its leadership and drive future success. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/beheradebasish_LATE_5795058_91338286_Spring2025_GeneDX.docx | Healthcare Profile | 76.9 | null | null | null | WGS
As of January 6, 2025, GeneDx shares closed at $89.61 | null | null | 5 | 4 | 5 | 4 | 4 | 4 | 5 | -1 | 5 | -1 | -1 | -1 |
Amwell is a leading telehealth company that connects patients with healthcare providers through a scalable, AI-powered platform designed for virtual consultations, remote patient monitoring, and seamless EHR integration. Founded in 2006 and headquartered in Boston, Amwell partners with hospitals, insurers, and employers to improve healthcare accessibility, reduce costs, and enhance patient outcomes. Its flagship Amwell Converge platform combines in-person, virtual, and automated care, offering services in urgent care, behavioral health, and chronic condition management. Backed by investors like Google, Anthem, and Philips, Amwell continues to innovate in digital healthcare despite financial restructuring challenges. | business.amwell.com | Public | Digitally empowering healthcare ambitions | Boston, Massachusetts | 2,006 | Anthem, Philips, Allianz, Teva Pharmaceuticals, Google | Growth | Amwell offers a range of telehealth services, including urgent care, specialty care, behavioral health, and chronic condition management. The company provides these services through its platform, which can be integrated into existing healthcare systems, allowing for seamless video consultations and electronic health record (EHR) integration. Amwell also offers the Amwell Converge platform, a hybrid care solution that combines in-person, virtual, and automated care to enhance patient experiences and outcomes. | Amwell addresses the critical issue of healthcare accessibility, affordability, and efficiency. Traditional healthcare systems often struggle with long wait times, high costs, and geographical barriers, limiting access to quality care. | Amwell’s platform enables virtual doctor visits, AI-driven patient engagement, and seamless integration with hospital networks, allowing for remote diagnosis, treatment, and follow-ups. | This solution offers convenience, cost-effectiveness, and high-quality care, making healthcare more accessible to a wider population. | Amwell has transitioned to a subscription-first business model, focusing on recurring revenue from healthcare providers and insurers rather than relying solely on per-visit fees. The company now generates most of its income through long-term SaaS contracts, offering scalable, white-labeled telehealth solutions to hospitals, employers, and payers. | Amwell leverages AI-driven telehealth technology, including HIPAA-compliant video conferencing, mobile applications for remote access, and seamless EHR system integration for streamlined provider workflows. The platform supports cloud-based scalability, real-time patient data analytics, and automated triage using AI-powered chatbots. Amwell also incorporates machine learning algorithms for personalized care recommendations and secure API integrations to connect with digital health applications, ensuring interoperability across healthcare systems. | Amwell has established itself as a key player in telehealth, offering an advanced, AI-powered platform that enhances healthcare accessibility and efficiency through virtual consultations and seamless EHR integration. Despite facing financial restructuring challenges, the company continues to innovate with its Amwell Converge platform, which integrates in-person, virtual, and automated care to improve patient outcomes. Backed by major investors like Google and Anthem, Amwell is shifting toward a subscription-driven model to drive long-term sustainability while competing in a rapidly evolving digital healthcare market. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/behmerblake_5723724_91294711_Spring2025_BusinessProfileFormat (2) (3).docx | Healthcare Profile | 254.36 | 806 | null | Approximately $128 million | NYSE: AMWL, around $7.87, 52 Week Low/High: $5.00 / $18.80 | Negative, with significant net losses | null | 4 | 2 | 4 | 4 | 3 | 3 | 4 | 4 | 5 | 4 | 4 | 5 |
Abridge is a healthcare technology startup founded in 2018 and based in Pittsburgh, Pennsylvania. The company focuses on applying artificial intelligence to streamline clinical documentation. Its flagship product uses generative AI to convert patient-clinician conversations into structured clinical notes, thereby helping healthcare providers reduce their administrative burden. Abridge's mission is to bring more focus to the patient-doctor interaction by automating one of the most time-consuming parts of healthcare. | https://www.abridge.com | Private | Let doctors be doctors again | Pittsburgh, Pennsylvania, USA | 2,018 | CVS Health Ventures, Kaiser Permanente | Growth | Abridge offers an AI-powered platform that generates medical documentation from clinician-patient conversations in real-time. The tool integrates into electronic health records (EHRs) and provides structured summaries, capturing important details like diagnoses, medications, and treatment plans. It is designed to help reduce physician burnout and improve the accuracy and speed of clinical documentation. | Healthcare providers face increasing administrative work, especially clinical documentation, which contributes significantly to burnout and reduced time for patient care. | Abridge automates the transcription and structuring of clinical conversations into compliant and usable EHR documentation using generative AI. | Empowering clinicians to focus on patient care by eliminating the time and stress of manual note-taking and documentation. | Abridge uses a B2B SaaS model with subscription licensing. The platform is licensed by hospitals and health systems and priced based on provider usage, with custom enterprise plans. | Abridge employs cutting-edge natural language processing (NLP), large language models (LLMs), and proprietary speech-to-text technology tailored for healthcare settings. It integrates with EHRs through secure APIs and is compliant with HIPAA regulations. | Abridge is reshaping how healthcare providers manage clinical documentation. By transforming real-time conversations between clinicians and patients into structured medical notes, Abridge addresses one of the most pervasive pain points in healthcare: time-consuming administrative tasks. With an innovative platform powered by generative AI and NLP, it enhances both clinician efficiency and documentation accuracy. Abridge has garnered significant institutional partnerships with organizations such as Yale New Haven Health and secured backing from major investors like CVS, Kaiser Permanente, and Mayo Clinic. Its integration into existing EHR systems demonstrates its utility and future scalability. With increasing burnout among medical professionals, Abridge’s mission of "Let doctors be doctors again" aligns well with current healthcare challenges. The company’s clear focus on automation, data privacy, and user-centered design places it in a strong position within the competitive healthtech AI landscape. Abridge represents a compelling case of how emerging technologies can meaningfully transform patient care. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/bhatiasuveer_LATE_5794124_91343017_Futurist Class Abridge Profile Assignment.docx | Healthcare Profile | null | 65 | Series B | N/A (Private company) | null | null | null | 5 | 4 | 5 | 4 | 3 | 4 | 4 | 5 | 4 | 5 | 5 | 5 |
Nabla is a healthcare technology startup specializing in AI-powered solutions for medical professionals. The company focuses on streamlining clinical workflows, enhancing patient communication, and improving the quality of care through advanced natural language processing (NLP) and machine learning technologies. Nabla’s tools help reduce administrative burdens on clinicians, allowing them to dedicate more time to patient care. | https://www.nabla.com | Private | Better antibodies by engineering targets, not engineering antibodies | New York, NY | 2,018 | FirstMark Capital, Artemis, Partech | Growth | Nabla AI Copilot: An AI-powered medical scribe that automatically generates clinical notes from patient interactions. AI Chatbot: Assists with routine patient inquiries, allowing healthcare providers to focus on complex cases. | Medical professionals face significant administrative burdens, particularly with documentation, leading to burnout and inefficiencies in patient care. | Nabla automates medical documentation and patient interactions, reducing paperwork and allowing clinicians to focus on treatment. | By leveraging AI, Nabla enhances efficiency, accuracy, and clinician well-being, leading to better patient outcomes and reduced healthcare costs. | Nabla operates on a B2B SaaS model, offering AI-powered documentation and workflow solutions to hospitals, clinics, and independent practitioners. | Nabla's platform integrates advanced NLP, machine learning, and speech recognition to extract key insights from conversations and automatically structure them into medical notes. | Nabla is at the forefront of AI-driven healthcare innovation, focusing on reducing clinician workload through automated medical documentation and patient communication tools. By integrating NLP and machine learning, Nabla has created an AI-powered Copilot that significantly reduces the time required for medical note-taking, enhancing efficiency and accuracy in healthcare settings. With strong leadership and a clear vision, Nabla has gained traction in the healthcare industry, securing funding and forming key partnerships with hospitals and clinics. While facing competition from other AI-driven medical scribe solutions, Nabla differentiates itself through its automation capabilities and commitment to improving clinician well-being. As the adoption of AI in healthcare continues to grow, Nabla is well-positioned to become a leader in AI-powered medical documentation, offering a transformative solution for modern healthcare challenges. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/caiyuxuan_5658052_91332338_Spring2025_BusinessProfileFormat (2).docx | Healthcare Profile | null | 20 | null | null | null | null | null | 5 | 4 | 5 | 4 | 3 | 4 | 5 | 5 | 4 | 5 | 5 | 5 |
Arrow DX is creating extremely sensitive chips for more sensitively detecting chemical and biological substances in solution. | https://arrowdx.com/ | Private | Precision Diagnostics Through AI & Nanotechnology | Boston, USA | 2,016 | Berkeley SkyDeck | Growth | Developing highly sensitive detection chips that can be incorporated into portable sensors. | Non-alcoholic fatty liver disease (NAFLD) affects 30% of the U.S population. Caused by excessive accumulation of fat in a person’s liver, NAFLD is asymptomatic in its earliest stages and challenging to detect. | Arrow Dx is developing highly sensitive detection chips that can be incorporated into portable sensors. | Fast, reliable, and flexible diagnostics for a wide variety of applications ranging from early-stage disease detection to environmental pollutant detection to quality control in the wine industry. | Arrow Dx aims to address the lack of accessible and affordable diagnostic tools, particularly for early screening of diseases like non-alcoholic fatty liver disease (NAFLD). By developing portable and cost-effective diagnostic devices, the company targets smaller healthcare providers, such as physician office laboratories and independent practitioners, enabling them to perform advanced diagnostics without the need for large-scale laboratory infrastructure. This approach not only broadens the availability of critical diagnostic services but also reduces reliance on invasive procedures like liver biopsies. | At the core of Arrow Dx's innovation is the development of highly sensitive detection chips that can be integrated into portable sensors. These chips utilize nanotechnology to detect chemical and biological substances in various solutions, including saliva, water, and other bodily fluids. The versatility of this technology allows for applications ranging from early disease detection to environmental pollutant monitoring and quality control in industries like winemaking. | Arrow Dx is an innovative biotechnology company focused on developing highly sensitive detection chips. These chips are designed for a variety of applications, including early disease detection, environmental monitoring, and diagnostics. The company leverages cutting-edge technologies to improve diagnostic accuracy and enhance healthcare outcomes. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/colnaz_LATE_5662511_91352628_ArrowDx.docx | Healthcare Profile | null | 0.2 | seed | N/A (Private company) | Not publicly traded | Estimated at 10-20% | null | 4 | 4 | 5 | 3 | 4 | 2 | 3 | 2 | -1 | 3 | 3 | 4 |
They focus on Adverse Childhood Experiences (ACEs) and early-life adversity, tackling their profound effects on personal well-being and intergenerational trauma. From behavior and epigenetics to physical health, their approach addresses how trauma is transmitted across generations, helping to create lasting change for both individuals and families.They leverage responsible AI to enhance their systems, focusing on reducing harm and doing no harm. Their technology enables personalized interventions and predictive behaviors, driving improved health outcomes while ensuring ethical and safe practices. | https://www.cepanoa.com | Private | Cepanoa is dedicated to transforming lives through human-centered care and responsible AI - starting with profunda health | Redwood City, CA | 2,023 | null | Growth | 1 paragraph to list the offerings, including products and services being sold. | Cepanoa health aims to help children handle trauma. | They provide affordable and accessible therapy solutions through technology to match patients with qualified advisors and doctors. | Cepanoa health provides a type of healthcare which has a holistic approach, which is not typically found in doctors offices or with therapists. | Advertising with personalized plans tailored to each patient. | Cepanoa leverages AI backed software in order to allow treatment to become more accessible for communities who have typically not received proper health coverage. | Cepanoa health succeeds in their mission to help children with trauma through increasing accessibility, something that has not been done before. Gomez, founder and CEO, holds this close to her heart as she is very connected to her company’s mission. Although they have not proceeded with any funding yet, they have successfully bootstrapped for the past few years. Cepanoa is early stage ore seed company, therefore there is not much to analyze about capital and financial management. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/corrylarissa_LATE_5614369_91339050_Spring2025_BusinessProfileFormat copy.docx | Healthcare Profile | null | null | Pre seed | null | null | null | null | 4 | 3 | 4 | 3 | 3 | 5 | 3 | 4 | 4 | 4 | 5 | 4 |
Abridge AI Inc. is a healthcare technology company founded in 2018 and based in Pittsburgh, Pennsylvania. It uses artificial intelligence to help doctors and nurses with their paperwork by turning conversations with patients into organized clinical notes. This makes documentation easier, giving healthcare professionals more time to focus on patient care. | https://www.abridge.com/ | Private | We Transform Conversations Into Insights With AI | Pittsburgh, Pennsylvania, USA | 2,018 | Elad Gil, IVP, Bessemer Venture Partners, Lightspeed Venture Partners, CVS Health Ventures, Redpoint Ventures, NVentures, among others | Hypergrowth | Abridge offers an AI-powered platform that records and transcribes medical conversations between clinicians and patients, generating structured clinical notes. These notes integrate seamlessly with electronic health record (EHR) systems, streamlining clinical workflows and allowing healthcare providers to focus more on patient care. | Healthcare professionals often face significant administrative burdens due to extensive documentation requirements, leading to burnout and reduced time for patient care | Abridge's AI-driven platform automates the transcription and structuring of clinical conversations, reducing the time clinicians spend on documentation. | Abridge’s AI-driven solutions streamline healthcare documentation, so healthcare teams can focus on what matters most: delivering the best care to people. | Abridge operates on a subscription-based model, partnering with healthcare systems and providers who pay for access to its AI documentation services. | The company's platform utilizes advanced machine learning and natural language processing techniques to accurately transcribe and summarize medical conversations. This technology ensures that the generated clinical notes are both comprehensive and compliant with medical documentation standards. | Abridge AI Inc., founded in 2018, is a healthcare technology company based in Pittsburgh, Pennsylvania. The company specializes in using artificial intelligence to streamline healthcare documentation by converting patient-clinician conversations into structured clinical notes. This innovation reduces the administrative burden on healthcare professionals, allowing them to spend more time on patient care. With strong leadership and a growing demand for AI solutions in healthcare, Abridge has positioned itself as a key player in the industry. Abridge's success is largely driven by its strong leadership (ranked 5) and excellent timing (ranked 5), which have enabled it to capitalize on the increasing need for AI-powered healthcare solutions. The company has secured substantial funding, providing a solid financial foundation for growth. However, Abridge faces challenges in resilience and pivots (ranked 2) and differentiation (ranked 3), as the rapidly evolving healthcare tech landscape requires constant innovation their product could be improved to be more comprehensive and flexible for different healthcare teams. Despite these challenges, Abridge's focus on reducing clinician workload and improving patient care positions it for continued success in the market. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/cortinadanica_LATE_5659051_91339399_Abridge AI.docx | Healthcare Profile | 50 | 457.5 | Series D | null | N/A not yet IPO | Estimated to be approximately 10 Million | null | 5 | 4 | 3 | 3 | 4 | 5 | 2 | 4 | 3 | 4 | 5 | 4 |
PicnicHealth is a series C1 health technology startup aiming to simplify health record management for both patients and healthcare researchers. They built a platform where patients can access and manage all of their medical records in one place at the same time allowing them to participate in healthcare research. On the other hand, they accelerate healthcare research process for researchers by providing them quick and easy access to medical data directly from patients. | https://picnichealth.com/ | Private | Healthcare Simplified with the Universal Patient Record | San Francisco, CA | 2,014 | B Capital Group, Felicis, Y Combinator | Hypergrowth | 1 paragraph to list the offerings, including products and services being sold. | Managing health records is messy | Unified Medical Record, a digital platform to keep everything in one place | Easily mange all health records in one place | The patient side is free. Partner with life science companies and charge them based on the data they want access. | PicnicHealth built a data management platform, a mobile software application, and a LLM agent, Picnic AI trained on over 32 million patient records that enhance the user experience. | PicnicHealth built a platform that addresses pain points for both patients and life science researchers. They designed an easy and minimalist patient side user experience for managing all health records along with a LLM chat based agent that quickly answer questions regarding their health records for users. On the other hand, they collaborate closely with researchers and big healthtech companies by offering them a more efficient venue of getting access to health data for accelerating the healthcare research. PicnicHealth has a strong leadership team and advisory board, along with beyond financial supports from major venture capital firms. Their unique product and business model will lead them into supergrowth soon as their flywheel is on the verge of spinning once they put some incentive into the patient side marketing. Then, they will have a network effect that serve as their greatest moat. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/daichen_LATE_5570840_91342609_Heath_BusinessProfileFormat.docx | Healthcare Profile | null | null | Series C1 | N/A (Private company) | null | null | null | 5 | 5 | 5 | 5 | 3 | 4 | -1 | -1 | -1 | 5 | -1 | 5 |
Clarify Health’s purpose is to take patient data and use its AI and machine learning models to interpret it and to create better personalized patient healthcare plans. The purpose behind this is to improve patient outcomes and to use resources more efficiently so as to increase stockholder value. | https://clarifyhealth.com/ | Private | Blueprinting a healthcare system that benefits all | San Francisco | 2,015 | 20 Investors | Growth | The company’s main product is its AI and machine learning models. With these, it is able to process patient and healthcare data to not only provide better plans for better patient outcomes, but it is also able to give C-suite executives better data on the operations of a given region. In doing so, the executives are able to see where resources are being used efficiently and where efficiency is lacking. | Patient healthcare regimes are too standardized and require more personalization in order to improve outcomes and efficiency. | AI and machine learning programs to analyze data and offer better information. | Clarify’s value proposition is that it wants to provide better information regarding patients to allow for better use of healthcare resources and to improve patient outcomes. | Subscription model for hospitals and other healthcare providers. | The company utilizes AI, predictive analytics, machine learning, and real-time patient navigation in order to guide patients and caregivers through personalized healthcare plans. The company hopes that by using this technology, it can help healthcare providers to produce personalized plans for each of their patients, as opposed to standardized models, in order to have better outcomes for the patients. | Started in 2015 by Jean Drouin and Todd Gottula, Clarify Health began with the purpose of attempting to improve patient experiences and improving efficiency within the healthcare system. In order to do this, it has focused on AI-powered tools in order to analyze data and provide necessary information to patients, providers, and executives. The company’s timing has worked well to coincide with the rise of AI, allowing for a more mature product, and overall seems to be on track to becoming a larger play in the healthcare industry as it promises to offer increases in stockholder value. The company appears to be well received by the market with its current valuation of $1.5 billion. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/diazgilberto_LATE_5577542_91338641_Spring2025_BusinessProfileFormat_HealthcareAI.docx | Healthcare Profile | null | 352.96 | 5 Rounds | null | null | null | null | 3 | 4 | 4 | 5 | 3 | 3 | 4 | 5 | 4 | 5 | 5 | 5 |
Olive AI is a healthcare AI company for automating healthcare operations through advanced robotic process automation (RPA) and AI technologies. | https://oliveai.com | Private | AI Workforce Built Specifically for Healthcare. | Columbus, Ohio, USA | 2,012 | Drive Capital, General Catalyst, Ascension Ventures | Growth | Olive provides intelligent automation solutions designed specifically for healthcare operations, including claims management, patient scheduling, and revenue cycle management. Olive’s AI platform leverages machine learning and robotic process automation to streamline administrative tasks. | Healthcare organizations face inefficiencies due to manual, repetitive administrative tasks. | AI-powered robotic automation that efficiently handles routine healthcare administrative tasks. | Olive reduces administrative workload, cuts operational costs, and enhances patient experience through automated workflows. | Subscription model, with recurring revenue based on the scope and scale of automation services provided. | Olive’s platform utilizes machine learning, NLP, and RPA technologies, integrating into existing healthcare IT infrastructures. | Olive AI successfully addresses the critical pain points of operational inefficiency in healthcare through its AI automation solutions. With it’s strong leadership, large financial backing, and a good value proposition, Olive reduces administrative burdens, allowing healthcare professionals to focus on patient care. Their targeted approach and innovative solutions have made them as a strong proponent in the healthcare AI automation space. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/ganesharvind_5717886_91337017_OliveAI_ArvindG_Spring2025_BusinessProfileFormat.docx | Healthcare Profile | 48.9 | 902 | N/A | At one point 4 billion dollars | null | null | null | 5 | 4 | 5 | 4 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 5 |
Avaneer Health, founded in 2020 by top industry leaders, is dedicated to transforming healthcare through enhanced seamless data exchange and transparency. The company’s mission is to eliminate inefficiencies in healthcare by providing a secure, decentralized network that facilitates real-time data sharing among payers, providers, and innovators. This collaborative approach aims to streamline processes, reduce administrative costs, and improve patient outcomes by ensuring that critical information is accessible when and where needed. | https://avaneerhealth.com/ | Private | Simplifying the Business of Healthcare | Chicago, Illinois | 2,020 | Aetna, Elevance Health, Cleveland Clinic, HCSC, IBM, PNC Financial Services, Sentara Healthcare | Growth | Avaneer Health offers Avaneer Coverage Direct™, a solution that delivers accurate, real-time health insurance coverage information by connecting payers and providers through a secure, peer-to-peer network. This approach reduces operational costs and enhances patient experiences by ensuring both parties have the latest coverage details, minimizing claim denials and administrative burdens. The company also offers a FHIR-based network that enables secure, real-time data sharing among healthcare entities. This simplifies the administrative process and ensures participants have control over their data. | Healthcare data exchange is inefficient. This leads to administrative burdens, claim denials, and delays in accessing insurance coverage information. | Avaneer Health provides a secure, peer-to-peer network and a FHIR-based platform that enables real-time data sharing between payers and providers. This ensures seamless access to up-to-date insurance and patient information. | Reduces administrative costs, minimizes claim denials, and maximizes efficiency, and thus enhances the patient and provider experience. | Subscription. Pricing details are not publicly available, but Avaneer Coverage Direct™ can save between $3.35-$5.75 per claim for providers and $1.65 per claim for payers. | Avaneer Health’s platform is built on a FHIR-based infrastructure that facilitates real-time, secure data exchange between healthcare entities. It uses blockchain technology to ensure data integrity and security. The network’s decentralized, peer-to-peer architecture allows participants to share data directly, eliminating intermediaries. Avaneer Health also employs services like Amazon S3 for content delivery and AWS for a scalable cloud infrastructure. | Avaneer Health is a success. They have positioned themselves as a transformative force in healthcare data exchange by tackling interoperability inefficiencies (through their decentralized, peer-to-peer network built on FHIR and blockchain), acquiring strong industry partnerships, and having a clear value proposition. Furthermore, its subscription model ensures scalability and reduces administrative burdens and claim denials. More importantly, its main service Avaneer Coverage Direct™ has shown great value, saving between $3.35-$5.75 per claim for providers and $1.65 per claim for payers. The company also acquired $50 million in its seed funding round from major healthcare organizations. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/gutierrezeduardo_5613693_91263962_Business Profile_ Healthcare.docx | Healthcare Profile | 5.7 | 50 | Seed | null | null | Between -20% and -50% | null | 5 | 4 | 5 | 4 | 2 | 4 | 3 | 5 | 4 | 5 | 5 | 5 |
Hinge Health is a digital healthcare platform that provides services intended to facilitate the treatment of musculoskeletal pain. The platform is available for both individual and organizational use, where employers can provide the platform’s services to employees at no cost. This feature allows for better employee health and higher retention and performance rates. The purpose of the application is to extend traditional physical therapy, by allowing individuals to meet with health professionals at their desired time and location, to take control of their pain and overall health. Users can simply connect with a physical therapist through a mobile application on their schedule. Within the application, users can access exercises that are designed by AI and demonstrated by professionals. Users receive real-time feedback and guidance on their techniques and approaches to exercises. Users can also meet directly with a care team to learn about their conditions, allowing them to set goals and stay on track. Hinge Health is dedicated to ensuring inclusive care for all which is why users have access to comprehensive care teams such as those in acute injuries, chronic pain, women’s pelvic health, pre- and post-surgery, and fall prevention. Users are also able to access a wearable device, known as Enso, which is FDA-cleared and calms MSK pain in minutes so members can receive drug-free pain relief. | www.hingehealth.com | Private | Let’s Get Moving! | San Francisco, CA | 2,014 | Duke Capital Partners, Alkeon Capital Management, Breton Capital Ventures, Industry Ventures, etc. | Growth | Aimed at treating musculoskeletal pain, Hinge Health provides a range of services to users. Ranging from on-demand care, health tips, exercise recommendations, and a wearable device. While the platform is completely digital, users can scroll through personalized health plans and exercise routines, tailored to their pain and needed care. Users can set up 1-1 appointments with certified professionals at any time of the day from their given location, where they can receive trusted advice on their health plan at no cost and can even be given wearable devices for drug-free pain relief. A competitive offering of Hinge Health is their partnership with employers and insurance plans, as they can provide these services for free to users. | Access to health care professionals in the physical therapy industry can treat musculoskeletal pain. | A mobile application with an easy-to-use interface and 24/7 accessibility to medical professionals and health advice. | Effective, accessible, professional, & personalized care treatments for all individuals and all pain types, for health control. | Annual subscriptions, partnered with 2,200+ companies, charged based on customer use, free to users but uses B2B model with employers/companies | Hinge Health uses advanced AI technology to provide comprehensive digital solutions for musculoskeletal pain. AI software is used within the Enso device for personalized pain-relief simulation and is used to track user motion when conducting exercises. This AI technology shows the medical professionals if exercise movements are done correctly, allowing them to provide feedback to patients. Additionally, Cisco Webex Meetings are used for audio, video, and web conferencing when it comes to the 1-1 meeting between providers and users. Cisco serves as a core provider to Hinge Health as the company’s main purpose relies on accessibility and digital communication. | Hinge Health is a successful company because of their partnerships with over 2000 companies and health plans, allowing them to work with employers to generate revenue. Through these partnerships, they are then able to offer employees treatment at no cost. Treatment plans which are personalized and effective as they are curated with the use of AI and certified professionals, ensuring users can take control of their health and remain informed. Additionally, the accessibility of the mobile application is extremely convenient as users do not have to worry about fitting appointments into their busy schedules. Instead, employees can get in contact with medical professionals at any time of the day from any location, which increases access to care and reduces chronic pain. Outside of employer partnership, the platform is also convenient for individuals looking for exercise recommendations and real-time guidance and feedback from medical professionals which they may otherwise have difficulty getting in touch with. The devices offered for pain relief are also desirable by many as they are FDA approved and are a drug-free alternative for pain relief. Aside from the services offered to users, I think the company has also succeeded due to strong leadership. Almost all individuals found on the c-suite team of Hinge Health have graduated from prestigious universities like Oxford and Duke and have pursued higher education up to master’s and PhD programs. In addition to education rates, the individuals all have previous experience at top companies like Google or have served in other c-suite positions providing them with experience they can apply to Hinge Health. The company’s leadership includes professionals who understand the medical field and business operations, which has led to tremendous success and the process of now going public. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/hassanyara_5727837_91338241_Spring2025_BusinessProfileFormat (Healthcare AI).docx | Healthcare Profile | 300 | 827.57 | null | N/A | null | null | null | 5 | 4 | 3 | 4 | 3 | 4 | 2 | 5 | 4 | 5 | 5 | 4 |
Ada is a global digital health company dedicated to improving human health through AI-driven medical guidance. Founded by doctors, the company leverages advanced technology to bridge the gap between medical knowledge and accessible healthcare. Ada's mission is to empower individuals and healthcare professionals with personal and accurate symptom analysis, enabling informed decision-making and prompt medical attention. Ada operates at the intersection of AI and healthcare, providing solutions for individuals, healthcare providers, insurers and governments. With over 13 million users and 32 million completed assessments, Ada’s platform enhances diagnostic efficiency, patient triage and cost reduction in global healthcare systems. | https://ada.com/ | Private | Health. Powered by Ada. | Berlin, Germany | 2,011 | Paul Wicks, Torsten Winkler, William Tunstall-Pedoe, Jurg Eckhardt | Growth | Ada Health offers AI-powered healthcare solutions designed to enhance accessibility and efficiency in medical services. Its core product, the Ada symptom assessment app, helps users analyze their symptoms and receive personalized health insights. Additionally, the company provides enterprise solutions that support triage, patient management and cost optimization for healthcare providers, insurers and governments. By leveraging AI, Ada supports early diagnosis, care navigation and digital health integration. | Ada Health seeks to address the gap in accessible and reliable healthcare guidance, helping users understand their symptoms and navigate the healthcare system efficiently. | Ada Health utilizes AI-driven technology for symptom assessment, analyzing user inputs to offer personalized health insights and guide them to appropriate medical care. | Ada Health offers an AI-powered symptom assessment app for individuals to manage their health, and offers enterprise solutions to partners aiming to improve healthcare services. | Ada Health follows a B2B and B2C business model, offering its AI-powered symptom assessment tool through subscriptions, partnerships and API integrations. Revenue comes from licensing agreements with healthcare providers, insurers, and employers who integrate Ada’s technology to improve patient engagement and streamline care. The company also provides a free-to-use consumer app, with monetization coming from health organizations and insurers that use Ada’s AI-powered triage system. With over 13 million users and 32 million assessments completed, Ada’s global adoption demonstrates the demand for AI-driven healthcare solutions. | Ada Health leverages AI and machine learning (ML) to power its symptom assessment and clinical decision support systems. By combining natural language processing (NLP) with a medical knowledge base, the platform accurately interprets users' input. Ada’s backend is built on cloud-based infrastructure for scalability and real-time data processing, ensuring fast and secure interactions. Additionally, Ada also integrates API solutions for seamless integration with healthcare providers, insurers and digital health platforms, making AI-driven health assessments widely accessible. | Ada Health's success is driven by its AI-powered symptom assessment, which provides users with quick and reliable health insights while seamlessly integrating with healthcare providers and insurers. With millions of downloads in over 130 countries, strong partnerships and a focus on clinical accuracy, Ada has positioned itself as a leader in digital health. Its research-focused approach and continuous AI advancements ensure credibility, user trust and long-term growth in the healthcare industry. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/hatakkajulie_5794665_91319875_H8 - Ada Health.docx | Healthcare Profile | 75 | null | 5 | null | null | null | null | 4 | 3 | 4 | 3 | 3 | 4 | 3 | 4 | 4 | 5 | 4 | 5 |
Alignment Healthcare was founded in 2013 and is a healthcare company focused on providing customized healthcare services to seniors through Medicare Advantage plans. The company emphasizes a patient centric approach that leverage technology and data analytics to improve health outcomes and streamline care coordination. By integrating clinical care with personalized support, Alignment Healthcare aims to offer a more effective and compassionate healthcare experience for the aging population. | https://www.alignmenthealth.com/ | Public | New Era of Aging | Orange, California, USA | 2,013 | Blackrock, T. Rowe Price Investment Management | Growth | Alignment Healthcare provides Medicare Advantage insurance plans that include 24/7 virtual care access, in-home visits, wellness programs, prescription delivery, and a concierge style support service called ACCESS On-Demand Concierge. Through its Care Anywhere program, high risk members receive in home clinical visits. Their proprietary Alignment Virtual Application platform helps predict patient risks and coordinates care efficiently. | Seniors often face fragmented, impersonal care systems with limited access and high costs, especially those with chronic or complex conditions. | Alignment delivers integrated, tech-driven healthcare with 24/7 support and personalized care coordination to improve senior health outcomes. | Alignment delivers compassionate, coordinated, and data driven healthcare services that empower seniors to live healthier and more vibrant lives. | Alignment Healthcare offers Medicare Advantage plans and receives fixed monthly payments from Medicare to provide comprehensive healthcare services. This model encourages the company to focus on preventive care and efficient resource use that aims to improve health outcomes while controlling costs. | Alignment Healthcare utilizes AVA, a technology platform that integrates real time data and predictive analytics to enhance patient care. AVA allow care teams to anticipate health issues and coordinate timely interventions to improve outcomes for senior members. | Alignment Healthcare is redefining senior care by offering personalized Medicare Advantage plans that integrate technology, data analytics, and compassionate service. Despite current financial losses due to strategic growth investments, the company's innovative approach positions it well to capture a significant share of the senior healthcare market. As Alignment Healthcare continues to expand its offerings and national footprint, it remains committed to its mission of improving health outcomes and reducing costs for the senior population. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/jiangkevin_5665005_91337942_Spring 2025 Business Profile Format Healthcare.docx | Healthcare Profile | 2,700 | 375 | null | 3.38 billion | NASDAQ: ALHC, 17.61 USD per share | Approximately -7.01% | N/A | 4 | 3 | 5 | 4 | 3 | 4 | 4 | 5 | 4 | 5 | 5 | 5 |
Enlitic operates as a healthcare AI company dedicated to managing medical imaging data for radiology workflow enhancement through standardized data management. The company started operations in 2014 by developing AI solutions for diagnostic support before moving to data management in radiology. Enlitic functions to “revolutionize healthcare through AI and data to support evidence-based decisions while advancing research and healthcare service delivery”. The platform at hospitals and imaging centers utilizes artificial intelligence to process imaging data which results in quicker accurate diagnoses and easier AI tool implementation in clinical settings. | enlitic.com | Public | Intelligence that cares. | Fort Collins, Colorado, USA | 2,014 | DCVC, Amplify Partners, Capitol Health, Thorney Investment Group, Marubeni Corp., etc | Growth | Enlitic provides its users with AI-driven tools to optimize medical imaging data management processes. The ENDEX system standardizes inconsistent DICOM metadata to achieve precise image labeling and display and the ENCOG system removes protected health information to support safe data sharing and research activities. Migratek provides efficient large-scale imaging archive migration services through Enlitic’s acquisition of Laitek technology. The solutions operate through Ensight which provides a complete data management system that automates organization processes and quality checks and governance tasks to produce a clean imaging layer suitable for clinical use and AI integration. | Radiology departments face challenges due to inconsistent and isolated imaging data which creates workflow interruptions. The lack of standardized labels or incomplete metadata on patient scans results in two major problems: hanging protocols become unusable and studies get incorrectly routed. Moving decades of legacy images between systems costs a lot of money and creates numerous errors while strict privacy rules make data sharing extremely challenging. The current issues result in wasted radiologist time while placing additional burdens on IT staff to resolve manual problems and prevent the implementation of AI tools that need properly structured data. | The data challenges are solved by Enlitic through its AI-driven data infrastructure platform. The platform automatically standardizes imaging metadata while cleaning and anonymizing the data and enabling smooth system migrations. | The platform from Enlitic enhances radiology workflow operations by boosting capacity and efficiency, resulting in time and money savings. | Enlitic functions as a B2B software company that generates revenue through recurring payments. The company offers its platform through healthcare provider subscriptions which include annual SaaS fees for ENDEX/ENCOG/Ensight usage alongside one-time services fees for Migratek migrations. The subscription-based system has been designed to produce continuous ARR. | The technology from Enlitic uses advanced machine learning to process medical imaging data while it automatically standardizes metadata and removes personal information while maintaining clinical quality standards. The AI models of this system achieve reliable results across numerous imaging datasets because they receive training on millions of diverse medical studies. The platform connects to PACS and cloud systems through DICOM and API protocols to process imaging data in real time by standardizing and tagging and anonymizing it before secure storage or downstream applications. | The healthcare AI sector now recognizes Enlitic as essential because the company focuses on image data standardization which represents the critical bottleneck slowing down both radiology workflows and AI deployment in the sector. Enlitic utilizes its AI platform to simplify data processes which results in reduced diagnosis times and streamlined system conversions together with better regulatory fulfillment. Enlitic has earned its place in the market through its well-defined business model and unique service offering alongside its adoption of new diagnostic areas that were experiencing market saturation. The company's approach receives initial support from major partners including GE HealthCare. The ongoing financial difficulties along with growth hurdles do not thwart Enlitic from becoming an essential component for digital medical imaging infrastructure. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/jicharliechengjie_LATE_5612424_91339953_Futurist Medical AI Company Reviecw - Enlitic.docx | Healthcare Profile | 1.9 | null | IPO | $30–35M (yahoo finance) | ASX:ENL, A$0.075 per share now, 52 week low A$0.0490 and 52 week high A$0.6500 | Negative operating margin | null | 4 | 3 | 5 | 4 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 5 |
Benchling was initially founded by Sajith Wickramasekara (CEO) and Ashu Singhal (President) in 2012 when they were in MIT. The founders had an academic lab where they believed that technology was not keeping up with the rate that science was changing. Their focus is a cloud-based platform to simplify scientific processes by have one place for experimental design, data management and collaboration.
The focus of Benchling is to improve biotechnology and standardize data that is produced from lab. Their main three focuses are “centralization, standardization, and automation”. Centralization of data is data in one place, standardized of data makes data stick to a specific form, and automated data captures data automatically. They also aim to integrate AI to address any shortcomings in the lab processes and simplify analysis. | https://www.benchling.com/ | Private | Unlock the power of biotechnology. | San Francisco, California, USA | 2,012 | Altimeter Capital, Franklin Templeton, Tiger Global Management, Lone Pine Capital, and more | Growth | Benchling offers a lot of products to simplify the biotech research process. The first thing it offers is an online notebook that is used in documentations. They also have tools for analyzing DNA, RNA and protein structures. They offer a registry to track cells and well as plasmids. They also offer an area to document inventory, as well as an area that provides data visualizations tools. Overall, their tools are cloud based and provide ease to the research process. | In general, Biotechnology research is a process that is inefficient and is not very organized. Currently most research uses an unadvanced method of managing data and analyzing it. | The main solution offered is a cloud platform to have a one stop shop for managing data, allowing for seamless collaboration and being as efficient as possible. | The value proposition of Benchling is that it allows a single platform to handle data management and analysis and simplify and organize the research process. | Benchling operates with a freemium SaaS model. This means that is has a free model for academic and industry researchers. However, for those who are not in this category they offer a subscription-based model where they are able to provide specific to those in different areas of life sciences. They have worked with everyone from small startups to large multinational corporations. As of May 2024, Benchling had hit an ARR of $210 million with 1.2K customers, with an average contract value of $175k per customer. | Benchling uses cloud computing to have a platform for data management. This also allows for them to scale with ease. Their main tools include an electronic lab notebook, laboratory information management system as well as data visualization and analysis tools. They have additional technology in place to make sure the data is as secure as possible. | Benchling is a biotechnology R&D company founded by MIT students Sajith Wickramasekara and Ashu Singhal. They saw inefficiencies in research processes and saw an opportunity to improve data management and analytics. They offer a subscription-based service to their clients as well as a freemium model.
Benchling offers cloud-based tools to enhance collaboration and efficiency. Tools they offer include an electronic lab notebook, design tools, workflow automation, and analytics tools. These tools enable biotech companies, academic researchers, and pharmaceutical firms to accelerate innovation.
Benchling has had strong financial growth and investment. As of May 2024, Benchling had hit an ARR of $210 million with 1.2K customers, with an average contract value of $175k per customer. They have also worked with a diverse group of companies including small startups and large corporations and continue to grow their client base. The company continues to push the boundaries of scientific research and pave the way for biotech companies. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/karivedasrihitha_5616975_91300199_Spring2025_BusinessProfileFormat (1).docx | Healthcare Profile | 210 | 412 | null | Benchling was valued at $6.1 billion as of 2024 | null | Benchling likely has gross margins in the 60-70% range | null | 5 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 5 | 5 |
Tempus is a technology company dedicated to advancing precision medicine through the practical application of artificial intelligence in healthcare. Founded in 2015 by Eric Lefkofsky, Tempus aims to revolutionize healthcare by empowering healthcare providers with cutting-edge tools and insights to improve patient outcomes. The company's mission is to harness the power of data and technology to personalize treatment plans and accelerate research.
Tempus is at the forefront of leveraging AI algorithms and machine learning to analyze vast amounts of clinical and molecular data. This approach enables the company to uncover patterns and insights that inform more targeted and effective treatment strategies. Tempus collaborates closely with healthcare providers, researchers, and pharmaceutical companies to tailor its solutions to meet specific stakeholder needs, driving innovation and improving patient care. | https://www.tempus.com/?srsltid=AfmBOoqxUHU-gYmx2QTGAb-7CWs5_DisYZ-Sn3OoYRmyOft5TSrOSmTc | Public | AI-enabled precision medicine | Chicago, Illinois | 2,015 | Personalis, Akrivia Health, 8Trip, Exicure | Growth | Tempus offers a comprehensive suite of products and services designed to advance precision medicine through the integration of artificial intelligence and data analytics. The company's primary offerings include genomic testing services, such as next-generation sequencing diagnostics, which provide detailed molecular insights for personalized treatment plans. Additionally, Tempus provides data and services for drug discovery and development, including its Insights and Trials platforms, which leverage a broad network of physicians to facilitate clinical trial matching and research collaborations. The company also offers AI-enabled solutions like Hub and Lens, proprietary software tools that allow healthcare providers and researchers to interact with the Tempus Platform and access its vast data library for enhanced clinical decision-making and research. | Solves the problem of inefficient and less personalized healthcare. | Leveraging artificial intelligence to analyze vast amounts of clinical and molecular data, enabling more targeted and effective treatment strategies. | Ability to revolutionize healthcare by harnessing the power of data and technology to provide personalized treatment options. | Revenue channels:
Partnership Fees: Tempus forms long-term alliances with hospitals, clinical centers, pharmaceutical companies, and patient advocacy groups. These collaborations involve knowledge exchange, research funding, technology integration, and data sharing agreements, generating income through one-time set-up fees, milestone payments, royalties, licensing revenues, or regular service fees.
Data Analytics Services: Tempus offers access to its vast data insights through annual subscriptions or per-use arrangements.
Health Economics Research: Tempus conducts cost-effectiveness analyses and comparative effectiveness studies, monetizing its expertise by consulting with government agencies, private payers, and provider networks.
Metrics:
Revenue Growth: 30% year-over-year revenue increase to $693 million in 2024
Gross Margins: Non-GAAP Data and Services gross margin reached 72.4% in Q2 2024
Projection: Expected to turn positive in 2025 with a projected $5 million for the full year | Tempus leverages a robust technology stack centered around artificial intelligence (AI) and machine learning (ML) to advance precision medicine. The company's Tempus Platform integrates various data types, including genomic, clinical, and imaging data, to provide actionable insights for healthcare providers and researchers. Tempus utilizes Large Language Models (LLMs) to analyze unstructured data, enhancing clinical care and research. Additionally, the company employs proprietary software tools like Hub and Lens, which facilitate interaction with the Tempus Platform and access to its vast data library. Tempus also develops AI models and algorithms, such as the Tumor Origin algorithm, to predict cancer origins and guide personalized treatment decisions. | Tempus AI's success can be attributed to its innovative approach to precision medicine, leveraging artificial intelligence to analyze vast amounts of clinical and molecular data. This enables healthcare providers to make more informed decisions, leading to improved patient outcomes. The company's strong leadership under Eric Lefkofsky has been instrumental in driving its mission forward, while its robust business model and strategic partnerships have facilitated rapid growth.
A key factor in Tempus AI's success is its ability to differentiate itself through cutting-edge technology and a comprehensive data library. This differentiation allows the company to offer unique solutions that address specific needs in the healthcare sector, particularly in oncology and other complex diseases. Additionally, Tempus AI's timing in entering the precision medicine market has been advantageous, capitalizing on the growing demand for AI-driven healthcare solutions.
Tempus AI's resilience and adaptability have also played crucial roles in its success. The company has continuously innovated and expanded its offerings to meet evolving customer needs and stay competitive in a rapidly changing healthcare landscape. Overall, Tempus AI's success is a testament to its commitment to innovation, customer satisfaction, and strategic growth strategies. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/kimgeoffrey_5627721_91337127_Spring2025_BusinessProfileFormat (Tempus).docx | Healthcare Profile | 693.4 | 1,345 | IPO (June 2024): $410.7 million | $8.84B | Stock Symbol: TEM (NASDAQ) Current Stock Price: $48.03
52-Week High: $91.45 USD
52-Week Low: $22.89 USD | -99.66% (2024) | null | 5 | 4 | 5 | 4 | 3 | 4 | 5 | -1 | 4 | 5 | 5 | 5 |
Nabla is a French startup specializing in AI-driven solutions for the healthcare industry. Their flagship product, Nabla Copilot, is an ambient AI assistant designed to alleviate the administrative burden on healthcare providers and reduce clinician burnout. The tool listens to clinical consultations and drafts notes summarizing key elements, such as patient medical history, symptoms, diagnoses, and prescriptions. Nabla has raised significant funding, including a $24 million Series B round, to expand its capabilities and adoption. The company has seen rapid growth, with over 20,000 providers adopting Nabla Copilot, and has formed strategic partnerships, such as with Kaiser Permanente, to further its reach and impact in the healthcare sector. | www.nabla.com | Private | The medical assistant that frees up your time | Paris, France | 2,018 | null | Growth | Nabla offers innovative AI-driven solutions tailored for the healthcare industry. Their flagship product, Nabla Copilot, is an ambient AI assistant designed to streamline clinical workflows and reduce administrative burdens on healthcare providers. By listening to clinical consultations, Nabla Copilot generates comprehensive and accurate notes that capture essential details such as patient history, symptoms, diagnoses, and treatment plans. This tool enhances the efficiency and accuracy of medical documentation, allowing clinicians to focus more on patient care. Additionally, Nabla provides platforms for direct communication between patients and healthcare professionals, further improving accessibility and quality of care. The company's solutions are built to integrate seamlessly into existing healthcare systems, making them accessible and beneficial for a wide range of medical practices and institutions. | Doctors spend excessive time on administrative tasks, reducing time spent on patient care and leading to burnout. | Nabla Copilot uses AI to transcribe patient conversations and generate structured clinical notes, integrating seamlessly with EHR systems. | Nabla reduces documentation time by up to 50%, allowing doctors to focus more on patient care, reduce burnout, and improve work-life balance. It enhances efficiency and accuracy in clinical documentation. | Subscription-based model with potential per-use pricing for additional features or services. | The tech stack likely includes advanced natural language processing (NLP) models, possibly leveraging GPT-3 or similar technologies, integrated with secure cloud infrastructure for data handling. The system is designed to ensure HIPAA compliance for protecting patient data, with user-friendly interfaces built using modern web development frameworks for seamless integration into existing clinical workflows. | Nabla has emerged as a pioneer in the healthcare technology sector with its groundbreaking ambient AI assistant, designed to revolutionize the way medical practitioners handle administrative tasks and enhance patient care. By harnessing the power of advanced natural language processing (NLP) and artificial intelligence, Nabla offers a seamless solution that transcribes doctor-patient conversations in real-time, generating comprehensive and structured clinical notes. These notes are automatically integrated into Electronic Health Record (EHR) systems, significantly reducing the time and effort traditionally spent on documentation. The company's innovative approach addresses a critical need in the healthcare industry, where practitioners often face burnout due to the overwhelming administrative burden. Nabla's technology not only streamlines workflows but also ensures accuracy and efficiency in clinical documentation, allowing healthcare professionals to dedicate more time to direct patient care. This shift has the potential to improve patient outcomes by enabling more focused and attentive interactions between doctors and patients. Nabla's success is underpinned by its strong commitment to data privacy and compliance with healthcare regulations, ensuring that sensitive patient information is handled securely. The platform's user-friendly design and ease of integration with existing systems have made it a favored choice among medical practitioners, further solidifying its position in the market. Led by a team of experienced entrepreneurs, engineers, and physicians, Nabla continues to push the boundaries of AI-driven healthcare solutions. The company's strategic focus on continuous innovation and customer-centric development has enabled it to stay ahead in the rapidly evolving healthcare technology landscape. With a clear value proposition and a robust technological foundation, Nabla is well-positioned to lead the transformation of medical practice, making it more efficient, effective, and patient-focused. As Nabla continues to grow and expand its offerings, it remains dedicated to improving the quality of care and the lives of healthcare professionals, ultimately contributing to a more sustainable and resilient healthcare system. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/kostlouis_5786705_91298810_Nabla_BusinessProfileFormat_Louis.KOST.docx | Healthcare Profile | null | 53.94 | Series B | $120.43M | Not publicly traded | null | Not publicly traded | 4 | 5 | 3 | 5 | 2 | 3 | 3 | 5 | 2 | 5 | 5 | 4 |
GRAIL is a healthcare company focused on catching cancer early—before it becomes hard to treat. They’ve developed a cutting-edge blood test that can detect cancer signals from over 50 types of cancer, even before symptoms appear. By using advanced sequencing and AI-driven analysis, GRAIL aims to make early detection more accurate, accessible, and routine, ultimately saving lives and reducing healthcare costs. | https://grail.com | Public | Detecting Cancer Early, Transforming Lives | Menlo Park, California, USA | 2,015 | Illumina, CPP Investments, Huangpu River Capital, PSP Investments | Growth | GRAIL’s flagship product, Galleri, is a groundbreaking multi-cancer early detection (MCED) test capable of identifying signals from over 50 types of cancer through a simple blood draw. The company also provides clinical studies, data analysis, and genomic research to further improve early cancer detection technology. | Late-stage cancer diagnoses significantly reduce survival rates and increase treatment costs. Current screening methods are limited to a few cancer types and fail to detect many cases early. | GRAIL’s Galleri test detects cancer at earlier stages by analyzing cfDNA (cell-free DNA) in blood, reducing the reliance on late-stage diagnostics. | Early cancer detection saves lives, reduces healthcare costs, and enables proactive treatment strategies, making widespread screening feasible and effective. | GRAIL operates on a B2B and B2C model, offering its Galleri test to healthcare providers, insurers, employers, and directly to consumers. Revenue is generated through test sales, subscription-based screening programs, and partnerships with health organizations. | GRAIL employs high-intensity sequencing, AI-driven data analysis, and machine learning algorithms to identify and classify cancer signals in cfDNA. | GRAIL, Inc. is a healthcare company specializing in early cancer detection through its Galleri® blood test, which screens for over 50 types of cancer. Using advanced genomic technology and AI, GRAIL aims to improve early diagnosis and reduce cancer mortality. Recently spun off from Illumina and now trading independently, GRAIL continues to expand its market reach and clinical validation efforts. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/kupkaamalie_5794043_91316536_Business Profile - GRAIL.docx | Healthcare Profile | 125.595 | 2,000 | 5 rounds | $942.63M | Now: $27.81, 52 week low: $12.33, high: $63.99 | 0.00% | -0.4038 | 4 | 3 | 5 | 4 | 3 | 4 | 5 | 5 | 3 | 5 | 4 | 5 |
Aidoc is a health tech startup on integrating Ai to medical imaging and radiology. The company develops Ai-based decision-support software that analyzes medical images in real-time to detect and flag conditions such as strokes, pulmonary embolisms, and brain hemorrhages. Aidoc's mission is to speed up diagnosis, reduce work load, at the same time improve patient outcomes by integrating Ai. | https://www.aidoc.com | Private | Always-on AI for radiology | Tel Aviv, Israel | 2,016 | Square Peg, Aleph, EDBI, General Catalyst | Growth | Aidoc offers FDA cleared AI-powered solutions that run in the background as radiologists work, identifying anomalies and prioritizing life-threatening cases. The product supports multiple pathologies across the body and integrates into existing PACS systems, improving hospital efficiency and diagnostic accuracy. | Radiologists are overwhelmed by large volumes of imaging data, leading to delays in diagnosis and increased rates of burnout. | Aidoc leverages AI to automatically analyze scans in real-time, helping radiologists prioritize urgent cases and make faster, more accurate decisions. | Accelerate time-critical diagnoses and improve patient outcomes with intelligent imaging workflows. | Aidoc uses a subscription-based SaaS model, selling its platform to hospitals and imaging centers. Customers pay a recurring fee based on the number of scans processed or active modules used. | Aidoc uses deep learning and convolutional neural networks (CNNs) trained on large medical datasets to detect pathologies. The solution integrates with existing radiology infrastructure via cloud-based APIs and complies with medical standards like HIPAA and DICOM. | Aidoc contributed to successfully integrating ML to radiology. Its real-time, always-on diagnostic feature have gained regulatory approval and are now used in leading hospitals across multiple countries. With strong funding, a focused leadership team, and proven clinical results. Aidoc Solves one of healthcare's most pressing challenges: time-sensitive diagnosis. Its adoption trajectory and product pipeline indicate a strong potential to scale. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/leejoonsung_LATE_5794341_91419259_Readings and Healthcare AI_ co business profile.docx | Healthcare Profile | 45 | 140 | null | null | null | null | null | 4 | 4 | 4 | 4 | -1 | 4 | 4 | 5 | 5 | 5 | 4 | 5 |
Verge Genomics is a San Francisco–based startup focused on transforming drug discovery through artificial intelligence and advanced genomics. Founded in 2015, Verge Genomics applies machine-learning methods to identify new therapeutic targets for challenging neurological diseases such as ALS and Parkinson’s disease. The company’s mission is to accelerate the discovery of life-saving therapies by integrating genomic data, cutting-edge computational models, and laboratory validation. | https://www.vergegenomics.com | Private | Accelerating cures for complex diseases with AI | San Francisco, California | 2,015 | ALS Investment Fund, DFJ, Wuxi AppTec, others | Growth | Verge Genomics’s primary offerings revolve around its AI-driven drug discovery platform, which integrates large genomic datasets and computational models to identify potential drug targets more efficiently. It collaborates with pharmaceutical companies and develops its own early-stage pipeline of drug candidates. | Traditional drug discovery is time-consuming, expensive, and has a high failure rate, especially in complex diseases such as neurological disorders. | An integrated platform that uses machine learning and genomic data to pinpoint the most promising therapeutic targets, helping to reduce time and cost in preclinical research. | Verge Genomics reduces the costs, risks, and timelines inherent in traditional drug discovery by combining large-scale genomic data, sophisticated algorithms, and a proprietary validation framework. | Verge Genomics partners with pharmaceutical companies in co-development deals and also develops in-house drug candidates for eventual licensing or acquisition. Revenue can come from milestone payments, licensing fees, and royalties from successful therapies. | Verge Genomics employs a proprietary AI/ML platform that analyzes large datasets of patient genomic information, identifies disease-relevant gene networks, and predicts the likelihood that a particular drug candidate will be effective. This tech stack includes: Machine learning models for analyzing transcriptomic and genomic data Cloud computing for large-scale data processing Proprietary algorithms to rank potential drug targets In-house wet-lab capabilities for validating computational predictions | Verge Genomics stands out in the AI-driven drug discovery sphere by focusing on complex neurological diseases, an area where traditional methods face significant obstacles. Their integrated approach—merging genomics data with machine learning—allows them to prioritize the most viable drug targets and streamline preclinical testing. This strategy appears promising, as evidenced by venture capital interest and partnerships with established pharmaceutical firms. Although still in a growth phase, Verge’s leadership and scientific team have a strong vision that appeals to collaborators and investors. The core value they bring lies in accelerating the pace of drug discovery while reducing costs, which, if successful, could lead to transformative treatments for diseases with few existing therapies. By leveraging AI to inform decision-making, Verge Genomics has the potential to reduce the high risk and attrition rates plaguing drug development, positioning the company as an emerging leader in AI-powered healthcare innovation. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/leemichelle_LATE_5618088_91361550_Verge Genomics.docx | Healthcare Profile | null | 50 | Series A, B | N/A (private) | N/A (private) | N/A (R&D–focused startup) | N/A (not publicly traded) | 5 | 4 | 5 | 4 | 3 | 4 | 4 | 4 | 3 | 5 | 4 | 5 |
Radiology Partners is among the biggest physician owned and physician led radiology practices in the nation, practicing at hundreds of hospitals and healthcare facilities across the country. With the vision of transforming radiology through quality care, innovation, and service, the company has keen focus on clinical excellence, superior service, and physician leadership. Radiology Partners fosters a collaborative approach that allows radiologists to shape change, drive improvement in patient outcomes, and advance healthcare delivery.
The company is committed to elevating the practice of radiology through a technology based platform and a strong emphasis on research, data analysis, and AI. With a national footprint and a strong local footprint in each of its markets, Radiology Partners provides integrated imaging services while being sensitive to the unique needs of each customer. Their core focus on quality improvement, operational efficiency, and patient-centered care has made them a leader in scaling radiology transformation. | https://www.radpartners.com/ | Private | Focused on our patients. Led by our physicians. Driven by our mission. | El Segundo, CA | 2,012 | Buyout/LBO by Advanced Radiology, SC | Growth | Radiology Partners is a leading provider of teleradiology, onsite imaging services to hospitals, outpatient facilities, and imaging centers. They provide imaging services including x-ray, CT, MRI, ultrasound, and nuclear medicine. They also provide a variety of clinical support services including quality assurance, peer learning, and operationalizing radiology workflows. They use machine learning with AI solutions to increase diagnostic accuracy and reduce turnaround times trained from well trained and experienced radiologists. | Radiology Partners addresses the problem of inconsistent radiology services and a national shortage of radiologists, which may result in delays in diagnosis, variation in quality, and decreased access to subspecialty knowledge. | Radiology Partners offers a scalable, physician-led radiology practice that blends national resources with local clinical expertise, state-of-the-art technology, and subspecialty availability to deliver consistent, high-quality imaging services not backed by high quality resources or specialists. | Radiology Partners offers collaborative radiology services through an innovative platform that allows physicians around the nation give quality information about their radiology questions and concerns. | Service/subscription based | Radiology Partners has a robust technology platform constructed upon advanced imaging systems, artificial intelligence (AI), and cloud-based workflow environments for enhancing diagnostic accuracy and streamlining radiology functions. The technology consists of AI-assisted image evaluation and clinical decision support technologies coupled with picture archiving and communication systems and radiology information systems to allow transparent data exchange and reporting. | Radiology Partners is a successful physician led imaging service that offers collaborative resources to help other physicians with radiology/imaging needs around the nation. The physician based service highlights the importance of having primary care physicians involved during the process to offer unmatched care and quality of its services. Their use of transformative technology like machine learning and AI is boosting their precedence in the sector by developing more timely and quality imaging services compared to others.
The growth of Radiology Partners due to their strategy of affiliation, with hospitals, outpatient, and health systems has been remarkable but still in the boundaries of providing patients good value. Their focus and priority on quality assurance has truly advanced an environment for innovative and flexible practice. As a result, Radiology Partners is now clearly positioned leading the way to re-evaluate the practice of radiology to appropriately deal with the shortage of radiologists and demand for specialty imaging with the service technology that will meet those needs. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/loubrandon_LATE_5568559_91343824_Spring2025_HealthcareProfileFormat.docx | Healthcare Profile | 2,000 | 2,120 | growth equity investments | Privately held company | null | 12.9% | null | 5 | 4 | 2 | 4 | 2 | 4 | 3 | 3 | 2 | 3 | 3 | 2 |
Alma is a healthcare company dedicated to improving access to high-quality, affordable mental health care by supporting therapists with tools to grow and manage their practices. Founded in 2018 and headquartered in New York City, Alma operates a digital platform that provides mental health professionals with insurance support, practice management tools, and a directory to connect with clients. The company enables therapists to accept insurance, reducing financial barriers for individuals seeking care. | helloalma.com | Private | Helping Therapists, Helping People | New York City, USA | 2,018 | Insight Partners, Optum Ventures, Cigna Ventures, Thoma Bravo | Growth | Alma offers a comprehensive platform for mental health professionals, including practice management tools, insurance credentialing support, and client-matching services. Therapists can streamline administrative tasks, accept insurance with ease, and grow their private practices while focusing on providing quality care. For clients, Alma provides an easy-to-navigate directory to connect with therapists based on insurance, specialties, and preferences. | Mental health care is often inaccessible due to high costs, insurance barriers, and limited provider availability. | Alma bridges the gap by enabling therapists to accept insurance while providing them with business support, making therapy more affordable and widely available. | Alma enhances accessibility to mental health care by empowering providers with financial and operational tools while connecting clients with suitable, in-network therapists. | Alma operates on a subscription-based model, charging therapists a membership fee for access to practice management tools, insurance support, and directory listings. The company also earns a portion of insurance reimbursements processed through its platform. | Alma leverages cloud-based practice management software, electronic health records (EHR) integration, and AI-driven client-provider matching. Its platform is designed for scalability, offering seamless insurance billing, scheduling, and analytics. | Alma over the years has positioned themselves as a leader in the mental health sector by addressing critical issues of both accessibility and affordability. By empowering therapists and giving them business solutions by simplifying insurance processing, Alma has made notable strides in improving mental health care delivery. Their rapid growth, strong investor backing, and focus on innovation make them a standout player in the healthcare industry. With constant increasing demand for mental health services, Alma is a well-positioned company that has the power to continue scaling while maintaining their missions to enhance mental health access for all. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/lozanovillasenorsantiago_5769687_91338054_healthcare doc.docx | Healthcare Profile | null | 230 | Series D | N/A (Private company) | null | null | null | 5 | 4 | 4 | 4 | 4 | 5 | 4 | 5 | 4 | 5 | 5 | -1 |
SOPHiA GENETICS is a pioneering healthcare technology company that harnesses advanced data analytics and artificial intelligence to transform the way genomic and clinical data are interpreted. The company’s core mission is to democratize data-driven medicine, empowering healthcare professionals and researchers worldwide to make informed decisions with greater accuracy and efficiency.
Founded with the vision of integrating complex bioinformatics into everyday clinical practice, SOPHiA GENETICS has developed a robust platform that streamlines genomic analysis for applications in oncology, rare diseases, and beyond. By converting vast amounts of genomic data into actionable insights, they are helping to reduce diagnostic errors and accelerate personalized treatment plans.
Committed to continuous innovation, SOPHiA GENETICS leverages state-of-the-art technologies and strategic partnerships to address critical challenges in precision medicine. Its focus on scalability, regulatory compliance, and patient-centric outcomes has positioned the company as a leader in an industry that is rapidly evolving. | https://www.sophiagenetics.com | Public | Democratizing Medicine Through Data-Driven Insights | Lausanne, Switzerland | 2,011 | Sofinnova Partners(1st), Wellington Partners, Kurma Partners, QIA | Hypergrowth | SOPHiA GENETICS offers a comprehensive AI-powered platform that supports genomic and clinical data analysis for diagnostic and therapeutic applications. Their flagship product streamlines the interpretation of complex datasets, aiding clinicians in precision oncology and rare disease diagnosis. | The overwhelming complexity of genomic data interpretation that hinders accurate and timely diagnosis. | An integrated, cloud-based platform that leverages machine learning to deliver actionable insights from genomic data, facilitating precision medicine. | Using high-quality, data-driven insights, SOPHiA GENETICS improves diagnostic accuracy, optimizes treatment plans, and ultimately enhances patient outcomes. | SOPHiA GENETICS operates primarily on a subscription-based model for its SaaS platform, complemented by usage-based pricing for clinical laboratories and healthcare institutions. The company also builds channel partnerships with diagnostic centers and hospitals. Key performance metrics include recurring revenue growth, the number of tests processed, and adoption rates among global healthcare providers. | The SOPHiA platform is underpinned by robust machine learning algorithms, secure cloud computing, and big data analytics. This technology stack allows for the rapid processing and integration of genomic and clinical datasets while maintaining compliance with stringent medical data privacy regulations. The platform’s interoperability with existing hospital IT systems and its continuous evolution through iterative improvements ensure that it remains at the forefront of precision medicine innovation. | SOPHiA GENETICS has emerged as a transformative leader in healthcare technology by tackling the critical challenge of interpreting complex genomic data. Its innovative, AI-driven platform streamlines diagnostic processes, empowering clinicians with actionable insights that enhance patient outcomes and reduce diagnostic delays. By integrating advanced analytics, cloud-based computing, and scalable machine learning, the company is democratizing access to precision medicine, ultimately driving higher standards in clinical care.
Underpinned by visionary leadership and a steadfast commitment to continuous innovation, SOPHiA GENETICS has secured a significant market share through strategic global partnerships and a robust, subscription-based business model. Its rigorous adherence to regulatory standards, effective market differentiation, and sustained operational excellence have solidified investor confidence. As the company expands its technological capabilities and market reach, it continues to set new benchmarks in precision healthcare, ensuring its role as a pivotal force in transforming modern medicine. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/manchandadivjotsingh_LATE_5795144_91345149_Business Profile - SOPHiA Genetics.docx | Healthcare Profile | 65.17 | null | IPO - 2021 | $245.95M | NASDAQ: SOPH : $3.68 | Negative 105% | NA - loss making | 4 | 3 | 3 | 4 | 3 | 4 | 4 | 5 | 4 | 5 | 4 | 5 |
PharmEasy is an Indian health-tech startup and online healthcare aggregator founded in 2015 that connects patients with local pharmacies and diagnostic centers for medicine delivery, diagnostics, and telehealth services. | www.pharmeasy.in | Private | To change the face of healthcare in India, one consumer at a time. | Mumbai, Maharashtra, India | 2,015 | Temasek and GSV | Growth | Through its platform, PharmEasy provides a full suite of healthcare solutions that encompass online prescription medicine delivery, OTC medicines, healthcare and wellness products, booking of diagnostic tests, and teleconsultation. The context for these services is a platform connecting users with local pharmacies and diagnostic centers for timely delivery of medicine and health checkups. The user experience includes subscription based healthcare plans and a B2B vertical itself for hospitals and clinics supplying medical equipment and pharmaceuticals. | Limited access to affordable medicines and healthcare services, especially in remote areas. | A tech platform for easy medicine orders, lab test bookings, and online doctor consultations. | Convenient, affordable, and accessible healthcare for everyone. | Commission-Based Sales: Charges partner pharmacies and diagnostic centers a commission per transaction. Subscription Model: Offers "PharmEasy Plus" for free deliveries and discounts. Advertising Revenue: Earns from sponsored product listings and healthcare ads. B2B Supply (VAD/VAR Model): Supplies medicines and medical equipment to hospitals and pharmacies. | uses advanced data analytics, artificial intelligence (AI), and machine learning (ML) to optimize supply chain logistics and personalize user experiences. The mobile and web applications are built using scalable cloud technologies to achieve high availability and security. Also, PharmEasy uses secure payment gateways, and follows strict data protection practices to protect user information. | The rise of telemedicine along with a network of partnered pharmacies and diagnostic services has been essential for PharmEasy to satisfy a critical need for increasingly accessible and affordable healthcare in India, especially in light of the speed in which healthcare services moved online due to COVID-19. It has been possible for PharmEasy to quickly scale across India due to its business model that targets both B2B, B2C and subscription services to meet the needs of a broad customer base. Its technology advances, such as leveraging AI and cloud-based applications to streamline logistics and customer experience, has added competitive advantages. PharmEasy has captured the attention the investment community, attracting substantial capital to support its continued expansion into additional healthcare services, including teleconsultation. While PharmEasy has been met with significant competition and operational challenges, the company's capacity to make rapid, yet successful pivots in the digital healthcare market, along with continued resilience presents worthy pathways to sustain its position. Finally, the company has also faced hurdles in the form of declining valuation and management turnover. In addition to increasing competition and evolving regulation, these represent headwinds to its growth. Nonetheless, PharmEasy remains well positioned for continued success in the rapidly shifting healthcare context and ecosystem in India through its continued commitment to the expansion of its offerings, customer experience, technology and infrastructure. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/nrmugheshkumar_LATE_5795003_91343514_Spring2025_BusinessProfileFormat.docx | Healthcare Profile | 5,664 | null | null | $710M (April 2024) | Private company (Not listed) | Not publicly disclosed | Not applicable (Private firm) | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 3 | 4 | 5 | 4 |
Insilico Medicine is a clinical-stage generative artificial intelligence (AI)-driven biotechnology company founded in 2014. The company's mission is to accelerate drug discovery and development using advanced AI technologies. Insilico focuses on connecting biology, chemistry, and clinical trials analysis using next-generation AI systems, including generative models, reinforcement learning, and other machine learning techniques. Their primary goal is to discover and develop innovative drugs for various diseases, including cancer, fibrosis, central nervous system disorders, infectious diseases, autoimmune diseases, and aging-related conditions.
The company has developed a proprietary AI platform called Pharma.AI, which consists of PandaOmics (target discovery), Chemistry42 (small molecule generation), and InClinico (clinical trial prediction). This integrated platform enables Insilico to rapidly identify novel targets, design new molecules, and predict clinical trial outcomes, significantly reducing the time and cost associated with traditional drug discovery processes. | insilico.com | Private | AI-powered end-to-end drug discovery and development | Cambridge, Massachusetts, USA | 2,014 | Value Partners Group, Warburg Pincus, Qiming Venture Partners, WuXi, HongShan, Hillhouse | Hypergrowth | Insilico Medicine offers a range of AI-driven drug discovery and development services, including target identification, small molecule design, and clinical trial outcome prediction. Their flagship product is the Pharma.AI platform, which integrates various AI technologies to accelerate the drug discovery process. The company has also developed a portfolio of 30 drug candidates, with 10 receiving IND clearance. Their most advanced candidate, Rentosertib, is in Phase II clinical trials for idiopathic pulmonary fibrosis (IPF). | The time-consuming and costly process of traditional drug discovery and development. | AI-powered drug discovery platform that significantly reduces time and cost while increasing the probability of success. | Accelerating the development of life-saving therapies by leveraging AI to redefine biopharmaceutical R&D. | Insilico employs a hybrid business model, combining internal drug development with out-licensing deals and collaborations. They generate revenue through pipeline out-licensing agreements and drug discovery collaborations with industry partners. | Insilico's technology stack is built around its Pharma.AI platform, which integrates generative AI, deep learning, and large language models. Key components include PandaOmics for target discovery, Chemistry42 for small molecule generation, and InClinico for clinical trial prediction. The company also utilizes advanced robotics in its fully automated Life Star1 laboratory. | Insilico Medicine has emerged as a leading force in AI-driven drug discovery, demonstrating remarkable success in a rapidly evolving field. The company's innovative approach, combining cutting-edge AI technologies with deep expertise in biology and chemistry, has positioned it at the forefront of the pharmaceutical industry's digital transformation.
Insilico's success can be attributed to several key factors. First, its strong leadership under founder and CEO Alex Zhavoronkov has guided the company through rapid growth and technological advancements. The company's ability to secure significant funding, including a recent $110 million Series E round, demonstrates investor confidence in its potential. Insilico's differentiated approach, leveraging its proprietary Pharma.AI platform, has enabled it to dramatically reduce drug discovery timelines and costs, addressing a critical need in the pharmaceutical industry.
The company's impressive pipeline of 30 drug candidates, with 10 receiving IND clearance, showcases the effectiveness of its AI-driven approach. The advancement of Rentosertib to Phase II clinical trials for IPF further validates the company's ability to translate AI-generated discoveries into potential therapies. Insilico's hybrid business model, combining internal drug development with strategic partnerships and out-licensing deals, has created multiple revenue streams and opportunities for growth. With its continued focus on innovation and strong market positioning, Insilico Medicine is well-poised to revolutionize drug discovery and development, potentially bringing life-saving therapies to patients faster and more efficiently than ever before. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/pantianyue_5795402_91316944_Spring2025_BusinessProfileFormat_tianyue_health.docx | Healthcare Profile | 70.5 | 110 | Series E | null | null | null | null | 5 | 4 | 5 | 4 | 4 | 4 | 4 | 4 | 3 | 5 | 5 | 5 |
Babylon Health was a digital healthcare company that used AI and telemedicine to provide cheaper and accessible healthcare services. Babylon offered remote consultations, medical advice, and health management through its platform, making healthcare more convenient for patients and reducing pressure on healthcare systems. The goal of Babylon Health was to make healthcare available to everyone, regardless of location and financial status. Babylon connected patients with healthcare providers through video calls, offering quick and personalized care. The company aimed to improve health outcomes, reduce wait times, and make healthcare easier to access for people around the world. | https://www.babylonhealth.com/en-us | Public | ‘We’re for health, for all’ | London, UK | 2,013 | Hard to list all but notable ones are Saudi Arabia’s PIF and Swedish Pension Fund | Bankrupt | Babylon Health offered many services, including AI-powered health assessments, remote consultations, and personalized health management tools. Their video consultations allowed patients to speak with healthcare providers about medical concerns. Babylon also offered a symptom checker powered by AI, prescription services, and health tracking features through their app. Additionally, the company provided health monitoring tools for managing chronic conditions, making it easier for patients to track their health and receive timely care. | Babylon solved issues of accessibility and cost in healthcare by providing telemedicine services that relieve stress on conventional hospitals and expand access. | Online platform to provide telemedicine services to patients. | Babylon’s value proposition was that their healthcare services are cheaper and faster than conventional healthcare services. | Babylon’s business model combined subscriptions, fixed-price offerings, and partnerships with healthcare providers. The subscription model provided patients with access to virtual consultations, health assessments, and health management tools. They also offered fixed-price services for one-off consultations or treatments. Babylon partnered with health insurance companies, integrating their platform into healthcare plans to expand its reach. They had over 2 million global users at their peak. | Babylon leveraged AI and machine learning technologies for its health assessments, symptom checker, and virtual consultations to analyze patient data and provide personalized medical advice. Babylon’s tech stack included cloud-based infrastructure for scalability and reliability. The platform also integrated telemedicine tools for secure video consultations and uses data analytics to monitor patient health and outcomes. | Babylon Health achieved success due to its mobile approach to healthcare, blending AI with telemedicine to create a platform that was accessible and affordable. The company’s use of AI powered providers to deliver higher quality and data driven healthcare to places where it wasn’t as accessible. Babylon scaled its services quickly, forming key partnerships with insurance companies, public health organizations, and global healthcare providers, which helped it expand its reach and build a significant user base. Despite facing challenges such as regulatory hurdles and competition in the crowded telemedicine space, Babylon Health’s ability to innovate and address real healthcare needs positioned it for success during its operational years. However, with the shutdown, it shows that even innovative companies must navigate complex financial and operational pressures to sustain long-term growth, even when revenues are in the billions like Babylons. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/patelrushi_5610698_91296204_Spring2025_BusinessProfileFormat (1).docx | Healthcare Profile | 1,100 | 1,200 | null | ~300 million | Symbol: BBLNF
Price currently: 0
Peak in 2021: $258 | N/A | N/A | 4 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 2 | 4 | 4 | 4 |
Corti is a Danish AI company offering a voice-based platform that helps healthcare practitioners analyze patient interviews in real-time. By using advanced AI, the platform enhances decision-making during medical consultations, enabling faster and more accurate diagnoses. | https://www.corti.ai/ | Private | We are on a mission to ensure everyone has access to medical expertise, no matter where they are | Brooklyn, New York | 2,014 | Atomico and Eurazeo are some of the investors. | Growth | Corti offers a variety of flexible products that can be used on their own, customized with an organization’s branding, or integrated into existing systems. Here are the key solutions they provide:
Ambient Scribe: Automates documentation during patient visits, saving time and increasing efficiency.
Automatic and Assisted Medical Coding AI: Improves revenue per visit, reduces claim denials, and streamlines coding workflows.
Call and Interaction Recording: Records and transcribes conversations, offering AI-driven insights to improve conversation quality.
AI-Ready Data Warehouse: Consolidates clinical, operational, and engagement data for actionable intelligence and trend analysis.
AI-Based Medical Dictation: Offers natural language dictation for accurate and automated EHR input.
Corti AI-Chat: A healthcare-focused AI chat agent that assists patients and supports providers in their workflows.
Intelligent Triage: Guides staff through protocols and questionnaires for compliant and productive triage interactions. | Healthcare practitioners spend considerable time on administrative tasks like documentation and coding, reducing time for patient care and increasing the risk of errors. | Corti’s AI platform automates documentation, coding, and patient interaction analysis, helping healthcare providers focus on patient care while improving efficiency and accuracy. | Corti helps healthcare professionals by automating tasks, improving decision-making, and streamlining processes, leading to better patient outcomes, lower costs, and more efficient workflows. | Corti operates on a subscription model, ensuring stable revenue and long-term client relationships. Key metrics include customer acquisition cost (CAC), monthly recurring revenue (MRR), customer retention rate, and lifetime value (LTV) to measure growth and profitability. | Corti uses AI, machine learning, and natural language processing to analyze patient interactions. Its cloud-based platform offers real-time processing, secure data storage, and seamless integration with healthcare systems, improving efficiency and compliance in medical workflows. | Corti is a Danish AI company that uses technology to improve healthcare. Its platform helps healthcare providers by automating tasks like documentation, medical coding, and decision-making during patient interactions. This makes healthcare work faster and more accurately. Corti is positioned well in the growing AI healthcare market and has raised strong funding to continue expanding. Their solutions are designed to help healthcare providers save time, reduce errors, and ultimately provide better care to patients. With its innovative approach, Corti is set to make a big impact in the healthcare industry. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/rostadsandsynne_5794130_91338045_Corti Company Description.docx | Healthcare Profile | 1.26 | 103 | null | null | null | null | null | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 5 | 4 | 5 | 4 | 5 |
Butterfly Network Inc. is revolutionizing healthcare with its handheld, whole-body ultrasound powered by proprietary Ultrasound-on-Chip technology. This affordable, pocket-sized device integrates seamlessly with cloud-connected software and a mobile app, making ultrasound imaging more accessible and practical in clinical workflows. | https://english.butterflynetwork.com/#News | Public | Bringing the power of ultrasound into your assessment, diagnosis and treatment | Burlington, MA 01803 United States | 2,011 | Baillie Gifford
Eldridge Industries
Fidelity Management & Research Company
Glenview Capital Management
Ridgeback Capital
Tenet Healthcare | Growth | Butterfly Network Inc. offers a range of portable ultrasound imaging solutions designed to enhance patient care. Their product is the Butterfly iQ series, which is handheld, whole-body ultrasound devices that can connect seamlessly with smartphones and tablets. | Making ultrasound easier | Portable ultrasound imaging | Make it easier to get an ultrasound, by making medical imaging more accessible and efficient. | Their business model combines direct sales of its ultrasound devices with subscription-based services for their software offerings. Their hybrid solution ensures a continuous revenue stream while providing customers with up-to-date tools and support. | Ultrasound-on-chip technology, which is a whole-body ultrasound device. | Butterfly Network is a success in the medical imaging industry with its groundbreaking Ultrasound-on-Chip technology. By developing a portable, handheld ultrasound device, the company has made ultrasound imaging more accessible and affordable for healthcare professionals worldwide. Butterfly's innovation has positioned the company as a leader in the ultrasound technology, particularly in underserved and remote areas. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/saetrevanessa_5794411_91298577_Butterfly Network.docx | Healthcare Profile | 92.056 | 81.7 | public offering | 573.85 million USD | Symbol: BFLY
Current price: 2.68 USD
52 week range: 0.67-4.98 USD | In Q4 2024: gross margin of 61.4% | null | 3 | 3 | 4 | 3 | 3 | 3 | 4 | 4 | 3 | 4 | 4 | 5 |
Biobot Analytics is a pioneering biotechnology company specializing in wastewater-based epidemiology. By analyzing sewage, Biobot transforms wastewater infrastructure into public health observatories, providing valuable insights into community health trends. Founded in 2017 by biologist Mariana Matus and architect Newsha Ghaeli, the company is headquartered in Cambridge, Massachusetts. | biobot.io | Private | Transforming wastewater into public health data | Cambridge, Massachusetts, USA | 2,017 | Y Combinator, Ekistic Ventures, Refactor Capital, Liquid 2 Ventures | Growth | Biobot Analytics turns wastewater into actionable public health data, detecting pathogens, illicit drugs, and other health indicators in real time. Its epidemiological reports help communities track outbreaks, assess public health measures, and identify emerging risks early. By combining molecular analysis with AI-driven insights, Biobot is transforming how health trends are monitored and managed. | Traditional public health monitoring methods often rely on clinical data, which can be delayed and may not capture asymptomatic cases. | By transforming wastewater into a source of public health data, Biobot enables early detection of disease outbreaks, monitoring of substance use trends, and assessment of public health interventions. | They provide the cost effective alternative monitoring solution that is not invasive and enabling proactive responses to emerging health threats. | Data as a Service Model, Subscription Model. As well as providing a consulting service for their customer | Biobot utilizes advanced molecular technologies and artificial intelligence to analyze sewage, transforming raw data into actionable public health insights. | Biobot Analytics has carved out a niche in wastewater-based epidemiology, offering a unique approach to public health monitoring by turning sewage data into actionable insights. The company has effectively leveraged its data-driven model to provide communities with early detection of outbreaks and trends, positioning itself as an essential tool for public health management. Its strong value proposition, well-timed market entry, and innovative product design have been key drivers of its success. While Biobot’s business model is solid and its financial management has been effective, differentiation remains a challenge as other players enter the wastewater analytics space. Leadership has navigated growth well, though resilience and adaptability could be stronger in responding to industry shifts. Marketing efforts have been effective in driving adoption, but continued expansion and visibility will be crucial for maintaining its position in the market. Biobot’s ability to meet customer needs and navigate regulatory frameworks has reinforced its credibility, and its focus on timing and innovation has kept it ahead of emerging trends. Moving forward, scaling operations and strengthening competitive advantages will be essential to sustaining growth. The company has built a strong foundation, but long-term success will depend on its ability to refine its strategy, enhance differentiation, and solidify its leadership in the industry. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/sawasdeeponnoah_5794019_91318768_Biobot Analytics-1.docx | Healthcare Profile | null | 2.5 | Seed | N/A (Private Company) | null | null | null | 3 | 4 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 5 | 5 |
Clipboard Health is a fast-growing healthcare technology company that connects healthcare professionals with job opportunities at healthcare facilities. The platform simplifies the hiring process by enabling healthcare providers to quickly find qualified professionals for open shifts. By leveraging technology, Clipboard Health aims to make the workforce management process more efficient, cost effective, and user friendly for both employers and employees.
The company’s mission is to improve the healthcare industry by addressing staffing challenges, promoting better work life balance for healthcare professionals, and providing quality care for patients. With a focus on innovation, Clipboard Health aims to streamline the staffing process and offer a platform that fosters connections, improves communication, and promotes growth within the healthcare workforce. Ultimately, the company is driven by its vision of transforming healthcare staffing through technology. | https://www.clipboardhealth.com/about | Private | We seek to revolutionize the market for healthcare talent by paving the way in reliability, affordability, and ease of use for both facilities and healthcare professionals. | San Franscisco, CA | 2,016 | Y Combinator and Initialized Capital | Growth | Clipboard Health offers a platform that connects healthcare professionals with open shifts at healthcare facilities, providing a seamless process for both works and employers. Their service includes job matching for various healthcare positions – nurses, aides, and other support staff – allowing professionals to select shifts that fit their schedule. The platform ensures that healthcare facilities can fill staffing gaps quickly with qualified individuals to improve operational efficiency and reduce labor cost. | Healthcare facilities often struggle to find qualified staff for open shifts which leads to staff shortages and increased operational strain. | Provides a tech driven platform that connects healthcare professionals to flexible job opportunities. | Providing efficient staffing solutions for all healthcare facilities. | null | null | Clipboard Health has emerged as a successful business in the healthcare staffing world by addressing the immediate need for flexible, digital solutions that connect healthcare professionals with employers. The company offers a platform that allows nurses to choose shifts based on their availability which streamlines the process for both healthcare workers and facilities. By capitalizing on the trends in the economy and the demand for flexible work, Clipboard Health has positioned itself as a key player in an industry traditionally characterized by difficult and inefficient staffing practices.
The company’s success is largely due to its strong market fit and value proposition. It meets the needs of healthcare professionals seeking better work-life balance while offering healthcare providers an efficient way to fill staffing gaps. Despite challenges with pay and service stability, Clipboard Health has built a loyal user base, with its leadership team and innovative business model driving significant growth. The company has also benefited from the timing of its entry into the market, aligning with the increasing demand for temporary healthcare staffing and digital workforce solutions. With continued adaptation to customer concerns, Clipboard Health has the ability to maintain its success and grow more in the competitive healthcare staffing landscape. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/shahpiya_5664667_91331767_Spring2025_BusinessProfileFormat_Healthcare.docx | Healthcare Profile | 279.1 | 94.1 | Series C | null | null | null | null | 4 | 4 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 4 | 4 |
Cala Health is a bioelectronic medicine company dedicated to transforming the standard of care for chronic diseases through innovative, non-invasive therapies. Founded in 2014 and headquartered in the San Francisco Bay Area, Cala Health combines advancements in neuroscience and technology to develop wearable neuromodulation devices that provide individualized peripheral nerve stimulation. | https://calahealth.com | Private | Wearable Medicine for People with Chronic Conditions. | San Mateo, California | 2,016 | Canaan Partners, Bessemer Venture Partners, Section 32, Sands Capital Ventures | Growth | Cala Health offers bioelectronic treatments through its wearable medical devices designed to manage chronic conditions, particularly focusing on essential tremor. Their flagship product, the Cala Trio, is a prescription device that uses neuromodulation technology to reduce hand tremors in patients. The company also provides Cala Connect, a software platform that enables patients and healthcare providers to track and manage treatment progress. In addition to these products, Cala Health is exploring other bioelectronic medicine solutions to treat various neurological and chronic conditions using non-invasive, drug-free technology. | Cala Health addresses the challenge of managing chronic conditions like essential tremor by providing non-invasive, drug-free solutions to reduce symptoms such as hand tremors. | Their wearable devices offer an alternative to traditional treatments, improving quality of life for patients with minimal side effects. | Cala Health’s value proposition lies in providing patients with chronic conditions, like essential tremor, a non-invasive, drug-free treatment option that significantly reduces symptoms, improving daily functioning and quality of life. | null | Cala Health uses neuromodulation technology in its wearable devices, like the Cala Trio, to reduce essential tremor symptoms through electrical stimulation. The devices integrate with Cala Connect, a cloud-based platform that tracks patient progress and provides insights for healthcare providers. The tech stack combines wearable hardware, biosignal processing, and data analytics to deliver personalized, non-invasive treatment. | Cala Health has been successful due to its innovative approach to addressing chronic conditions like essential tremor with non-invasive, drug-free wearable devices. The company recognized the need for alternatives to traditional treatments such as medication and surgery, offering patients a more convenient and safer solution through its neuromodulation technology. By providing an easy-to-use wearable device, the Cala Trio, along with a data-driven platform for patient monitoring, Cala Health has been able to meet a significant market demand in the healthcare sector.
Cala Health’s success can also be attributed to its strong leadership, particularly from co-founder and CEO Dr. Kate Rosenbluth, who has a background in both healthcare and technology. The company has built a culture of innovation and patient-centric care, ensuring that its products are not only effective but also accessible. The strategic partnerships with investors have enabled Cala Health to secure the funding necessary for product development, clinical trials, and market expansion, while its ability to navigate the complex regulatory landscape has allowed for widespread adoption of its products.
Additionally, Cala Health has differentiated itself from competitors by focusing specifically on wearable bioelectronics, which is a growing niche in the medical device market. With a solid value proposition and clear focus on improving patients' quality of life, the company continues to expand its reach. The success of Cala Health demonstrates how combining cutting-edge technology with a patient-focused approach can lead to tangible results in the healthcare industry. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/solorzanomariaisabella_5611636_91315321_Spring2025_CalaHealth.docx | Healthcare Profile | 15 | 99 | Series B | N/A (Private company) | null | null | null | 5 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 4 | 5 | 4 | 5 |
Abridge is a medical AI company founded in 2018, headquartered in Pittsburgh, Pennsylvania. Its mission is to deepen understanding of healthcare by transforming doctor-patient conversations into real-time, structured clinical records. Abridge uses enterprise level generated artificial intelligence and deep electronic medical record integration to help clinical doctors record more effectively and focus on patient care. The platform was built with transparency and trust in mind, and set high standards for responsible artificial intelligence in medicine. | https://www.abridge.com | Private | null | Pittsburgh, Pennsylvania, United States | 2,018 | IVP, Elad Gil | Growth | Abridge provides AI tools that convert real-time conversations between doctors and patients into structured notes, and integrate them with electronic medical record systems to improve document efficiency and reduce the burden on doctors. The service includes recording, transcription, summarization, and review, suitable for medical institutions and individual practitioners. | Clinical documentation is time-consuming and takes doctors' attention away from patients. | Abridge uses AI to turn medical conversations into structured notes in real time. | It helps doctors save time and focus more on patients, improving both care and workflow. | Abridge adopts a subscription based model to provide AI based document tools for healthcare providers. Hospitals and clinics pay to access the platform, which helps improve efficiency and reduce clinical fatigue. | Abridge utilizes natural language processing (NLP) and machine learning to convert real-time doctor-patient conversations into structured clinical records. It integrates with major electronic health record (EHR) systems and uses secure cloud based infrastructure to ensure data privacy and compliance with healthcare regulations. | Abridge has become an outstanding medical AI startup by completely changing the way clinical conversations are recorded. Its AI driven platform converts real-time doctor-patient conversations into structured notes, which helps reduce administrative burden and improve efficiency. With strong growth, solid funding, and high recognition in KLAS rankings, Abridge has demonstrated the value of focusing on healthcare innovation. Its success lies in combining generative artificial intelligence with deep EMR integration, directly addressing the main pain points of clinical doctors, thereby providing better care and saving time. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/tanzunyu_5671125_91338223_Spring2025_BusinessProfileFormat (Healthcare).docx | Healthcare Profile | null | 57.5 | Funding over 4 rounds | N/A | N/A | null | N/A | 5 | -1 | 5 | 5 | 4 | 5 | 4 | 5 | 5 | 5 | 5 | 5 |
Garner’s mission is to allow people to get access to high-quality and affordable healthcare. Garner attempts to use data-driven insights and financial incentives to ensure patients get the best care possible and stay healthy. Moreover, Garner hopes to promote high-quality healthcare and willingness to improve by rewarding top healthcare organizations by connecting them to more patients. | getgarner.com | Private | null | New York City, NY | 2,019 | Redpoint, Founders Found, Thrive Capital, Optum Ventures, Maverick Ventures, CoFound Partners, BoxGroup | Growth | Garner helps companies’ employees to find the best doctors and healthcare within their network. Garner also helps employees save money on copays when visiting top doctors. Garner DataPro offers data-driven insights to other healthcare organizations so that they can improve their services and also get referred Garner users based on how well they do. | Finding the correct healthcare is often confusing and not transparent. Furthermore, copays and deductibles tend to catch people off guard. Finally, healthcare organizations struggle with efficiency and patient satisfaction. | Garner offers a platform that clearly lays out healthcare options, highlighting the best ones. Garner covers costs when going with certain top organizations. Garner also offers data insights for healthcare organizations to improve themselves. | Using Garner’s platform, employer’s will benefit from healthier, happier and more productive employees. Employees can find the best healthcare at low costs. Healthcare organizations are able to obtain advice and insights from a platform that deals with potential patients. | Garner has a B2B business model. Employers pay so their employees can have access to this platform. Healthcare organizations pay to get access to Garner’s support and data-driven insights. | Garner uses data science and machine learning to offer data-driven insights to healthcare organizations while also using it to suggest the best healthcare to patients. Garner uses cloud technology through AWS and Snowflake. | Garner health was and continues to be successful because of its approach to simplifying healthcare. Today, healthcare options tend to be too complex or not transparent, so a patient can never understand how to get the best care they need. Garner successfully solves this problem by connecting patients to the right organizations so that they can get the best care with little to no cost. Moreover, Garner’s ability to provide data-driven insights to healthcare organizations is extremely valuable to those organizations. These organizations will know how to better tailor their services to potential patients. Garner Health is also popular among employers as it has been proven to reduce the average number of sick days taken by employees. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/tatikondanithin_5568199_91323342_Garner Health Profile.docx | Healthcare Profile | null | 70 | null | null | null | null | null | 3 | 3 | 2 | 4 | 1 | 3 | 2 | 4 | 5 | 4 | 3 | 3 |
The mission of the company is to bring life-saving technology to everyone, regardless of their race, ethnicity, gender, religion or location. They believe that everyone deserves and should have equal access to medical care. They provide flexibility for its customers in that they can test at their own convenience at home, or wherever they want to do the test. | https://healthy.io/ | Private | Healthcare at the speed of life | Tel Aviv, Israel | 2,013 | null | Hypergrowth | Healthy.io offers AI-powered diagnostics, including Minuteful Kidney for at home chronic kidney disease testing, Minuteful UTI for rapid UTI diagnosis, and AI-driven Wound Care for remote monitoring. The products are sold via healthcare providers, insurers, and pharmacies. | Healthy.io eliminates barriers to lab testing by enabling at-home, AI-powered diagnostics for chronic kidney disease, UTIs, and wound care. Traditional testing requires clinics, long wait times, and high costs, leading to delayed diagnoses and untreated conditions. | Healthy.io's solution leverages AI and computer vision to transform smartphone cameras into clinical-grade diagnostic tools. This platform enables patients to perform tests at home—by capturing images of test strips for conditions like chronic kidney disease, UTIs, and wound care—and provides instant, accurate analysis of chemical changes. | Their value proposition lies in transforming smartphone cameras into clinical-grade medical devices, enabling at-home diagnostics for conditions like chronic kidney disease and wound care. By leveraging AI and machine learning, they provide lab-accurate results remotely, improving access to healthcare, early disease detection, and patient convenience, while reducing healthcare costs and gaps in care. | Healthy.io primarily operates under a Channel Business Model with elements of a VAD/VAR model. They partner with healthcare providers, pharmacies, insurance companies, and health systems to distribute its products rather than selling directly to consumers themselves. It also integrates fixed pricing for its B2B clients and subscription-based models in certain partnerships. | Healthy.io leverages AI-driven image processing, machine learning, and computer vision to turn smartphone cameras into clinical-grade diagnostic tools. Built on cloud infrastructure its platform ensures EHR compatibility, HIPAA/GDPR compliance, and real-time health insights for seamless patient-provider interactions. | Healthy.io’s success can be attributed to its unique value proposition, timing in the market, and strong leadership. By transforming smartphone cameras into clinical-grade medical devices, the company has effectively solved a major pain point in healthcare: the need for accessible, accurate, and remote diagnostics. Its FDA-cleared AI-powered urinalysis and wound care solutions provide lab-quality results from home, reducing barriers to early disease detection and treatment. This innovation aligns perfectly with growing trends in telehealth and digital health, allowing the company to stand out in a crowded market.
Unlike many startups that struggle with healthcare compliance, Healthy.io prioritized regulatory approvals (FDA, CE) early on, earning credibility among healthcare providers, insurers, and governments. Their B2B partnerships with health systems and pharmacies helped scale adoption faster than a direct-to-consumer (DTC) approach alone. Additionally, the company has demonstrated resilience by expanding from urinalysis to AI-driven wound care, proving its ability to pivot and scale based on market needs.Lastly, strong leadership and financial backing played a critical role. Founded by Yonatan Adiri, a well-known innovator in digital health, Healthy.io has secured over $190M in funding, allowing it to continuously improve its AI models, expand globally, and establish long-term sustainability. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/throneholstsina_5794404_91298730_Healthy-1.io.docx | Healthcare Profile | 189.97 | 50 | null | null | null | null | null | 5 | 4 | 5 | 4 | 3 | 4 | 5 | 5 | 5 | 5 | 5 | 5 |
Neko Health is a Swedish health-tech startup co-founded by Spotify’s founder Daniel Ek and entrepreneur Hjalmar Nilsonne, specializing in preventive healthcare through AI-assisted full-body scanning technology. Using 70 sensors to collect over 50 million data points in a 10-minute session, the company’s non-invasive scans analyze skin health, cardiovascular function, and metabolic indicators. With clinics in Stockholm and London, Neko Health has performed over 10,000 scans. The company’s mission is to revolutionize healthcare by shifting from reactive treatment to proactive prevention. By leveraging advanced imaging and AI-driven analysis, Neko Health aims to detect potential health issues early, helping individuals take control of their well-being and reduce long-term healthcare costs. With an expanding global waiting list, the company is focused on scaling its technology and entering new markets, including the U.S., to make preventive healthcare more accessible and data-driven. | https://www.nekohealth.com/se/en | Private | Shifting healthcare from reactive treatment to proactive prevention | Stockholm, Sweden | 2,018 | Lakestar, General Catalyst, Atomico, Lightspeed | Growth | Neko’s primary offering is the Neko Body Scan, which utilizes 70+ sensors and AI analysis to detect potential health issues early, analyzing, e.g., skin anomalies. The scan takes about 10 minutes, with real-time results provided during a doctor consultation. Neko Health also offers personalized health insights, enabling users to track changes over time via a digital platform. | The late detection of serious health conditions due to a reactive healthcare system that focuses on treatment rather than early prevention. | AI-powered, non-harmful full-body scans that enable early detection of health risks, shifting healthcare from reactive treatment to proactive prevention. | Helping people to stay ahead of health risks before they become serious. It’s all about shifting from reactive treatment to proactive prevention so that customers can take control of their health. | Neko Health operates on a fixed-price, direct-to-consumer (DTC) business model, where customers pay a one-time fee per full-body scan. Each scan costs approximately €250-€300 and includes an AI-driven health analysis with a doctor consultation. | Neko’s full-body scan system uses 70+ advanced sensors to capture detailed health data. AI-driven algorithms then analyze millions of data points in real time, identifying potential health risks with greater accuracy and efficiency than traditional check-ups. This data is instantly processed and visualized for both patients and doctors, allowing for immediate insights and personalized health recommendations. By combining machine learning, computer vision, and real-time analytics, Neko Health is making preventive healthcare more accessible, data-driven, and proactive. | Neko Health is a success because it makes preventive healthcare fast, affordable, and accessible. Its AI-powered full-body scans provide real-time health insights in just 10 minutes, empowering people to detect risks early instead of waiting for symptoms. With 100,000+ on its waitlist and $260M in funding, demand proves the need for scalable, proactive health solution. Unlike costly, time-consuming MRI scans, Neko’s efficient AI-driven approach bridges the gap between innovation and everyday healthcare, making early detection mainstream. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/wimmersimon_5793578_91292754_Healthcare Business Profile_Simon Wimmer.docx | Healthcare Profile | null | 250 | Series B | null | null | null | null | 5 | 3 | 4 | 2 | 4 | 5 | 4 | 5 | 3 | 4 | 5 | 5 |
Navina is a healthcare AI startup founded in 2018 that specializes in AI-driven clinical decision support. Its platform integrates seamlessly with electronic health records to help physicians process patient data more efficiently. The company’s mission is to empower healthcare providers with AI-powered insights to improve patient outcomes, reduce administrative burden, and enhance decision-making. By leveraging artificial intelligence, Navina bridges gaps in healthcare data interpretation and provides accurate, timely, and actionnable recommandations. | https://www.navina.ai/ | Private | AI that thinks like a doctor. | New York | 2,018 | ALIVE Israel HealthTech Fund, Grove Ventures, Vertex Ventures Israel, Schusterman Family Investments | Growth | Navina provides an AI-powered clinical decision support system designed to work with EHRs. The platform analyzes patient data, highlights potential diagnoses, identifies risk factors, and flags medication conflicts. By simplifying complex data, Navina helps doctors make faster, more accurate decisions, improving both efficiency and patient care. | Doctors spend too much time sifting through fragmented patient records, increasing the risk of errors and inefficiencies. | Navina’s AI consolidates and organizes patient data, presenting key insights in an easy-to-digest format for physicians. | Navina saves doctors time, reduces burnout, and improves patient care by making clinical data more accessible and actionable. | Navina operates on a subscription-based model, charging healthcare providers for access to its AI-powered platform. The company partners with hospitals, clinics, and insurers to integrate its technology into their existing workflows. | Navina uses machine learning and natural language processing to extract insights from structured and unstructured medical data. The platform integrates with major EHR systems and applies AI-driven risk stratification, predictive analytics, and clinical decision support to enhance patient care. | Navina has emerged as a leader in AI-driven clinical decision support by tackling one of healthcare’s biggest challenges: physician burnout from overwhelming administrative work. By streamlining the way doctors interact with patient data, Navina enhances efficiency and improves diagnostic accuracy. With a strong leadership team, significant investment backing, and growing industry adoption, Navina is well-positioned for continued success. Its AI-driven approach not only reduces time spent on paperwork but also enhances patient outcomes by providing clearer insights. As AI continues to transform healthcare, Navina stands out as a company that bridges the gap between data and decision-making, ensuring better care for patients and less stress for doctors. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/wusamantha_LATE_5659854_91343834_Spring2025_BusinessProfileFormat - Healthcare-1.docx | Healthcare Profile | null | 100 | Series C | N/A (Private company) | null | null | null | 5 | 4 | 5 | 4 | 3 | 4 | 5 | 5 | 4 | 5 | 4 | 5 |
Pfizer Inc. is a global healthcare company that develops and sells medicines and vaccines to help people stay healthy. Based in New York City and founded in 1849, Pfizer serves patients in the United States and around the world. The company offers treatments for a wide range of health conditions, including heart issues, migraines, infections, and chronic illnesses. Some of its well-known products include Eliquis for heart health, Nurtec ODT and Zavzpret for migraines, and vaccines like Prevnar and Abrysvo to help prevent infections. Pfizer also played a major role in the fight against COVID-19, developing the Comirnaty vaccine and Paxlovid treatment. In addition, the company provides medicines for conditions related to the immune system, rare diseases, hormone imbalances, and cancer. Its cancer treatments include widely used drugs like Ibrance and Xtandi. Pfizer also supplies medicines to hospitals and clinics, including antibiotics and injectable drugs, and helps other companies manufacture their products. The company works closely with partners like Bristol-Myers Squibb, Astellas Pharma, Merck, and BioNTech, and serves customers such as hospitals, pharmacies, healthcare providers, and government agencies. | https://www.pfizer.com/ | Public | Breakthroughs that change patients' lives | NY, New York | 1,849 | null | Growth | At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. They strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Pfizer’s global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, Pfizer has worked to make a difference for all who rely on them. | Pfizer aims to solve the global need for effective, accessible treatments and vaccines for serious and widespread health conditions. | innovative, science-based medicines and vaccines that prevent illness, treat disease, and improve health outcomes worldwide. | Pfizer delivers innovative, science-driven medicines and vaccines that improve lives by addressing some of the world’s most pressing health challenges, combining cutting-edge research with global scale to make high-quality healthcare accessible to millions. | null | Technology: Pfizer leverages cutting-edge digital technologies—including AI, machine learning, real-time data modeling, remote monitoring, IoT sensors, and augmented reality—to accelerate drug development, scale global manufacturing, and ensure safe, efficient distribution of its medicines and vaccines. During the COVID-19 pandemic, these tools enabled Pfizer to rapidly develop and distribute over 3 billion vaccine doses worldwide, making it one of the most significant digital transformations in modern healthcare. | Pfizer Inc. is a leading global biopharmaceutical company committed to discovering, developing, manufacturing, and delivering innovative medicines and vaccines that improve lives. Headquartered in New York City and founded in 1849, Pfizer operates in over 125 countries and serves patients worldwide across a broad range of therapeutic areas including infectious diseases, oncology, immunology, cardiology, and rare diseases. The company played a pivotal role in the global response to the COVID-19 pandemic through its partnership with BioNTech, developing Comirnaty, the first FDA-approved mRNA COVID-19 vaccine, and Paxlovid, an antiviral treatment. Pfizer’s digital transformation—driven by investments in AI, machine learning, and advanced manufacturing—has accelerated its ability to bring products to market efficiently and at scale. With a robust product pipeline, strategic global partnerships, and a strong focus on science and innovation, Pfizer continues to address some of the world’s most pressing health challenges, while advancing its mission to deliver breakthroughs that change patients’ lives. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/xuchristine_LATE_5617342_91342481_Pfizer Inc.docx | Healthcare Profile | 63.6 | null | null | 148.14 billion | PFE(NYSE) – 31.54 (high), 24.48 (low) | 15.9% | 8.85 | 3 | 4 | 3 | -1 | 4 | 3 | 5 | 4 | 4 | 4 | 4 | 3 |
Atomwise strives to transform drug discovery and create better medicines using AI engines. This is achieved through the finding of small molecule drugs using a machine learning engine that combines neural networks and chemical libraries. | atomwise.com | Private | Better medicines faster | San Francisco, CA | 2,012 | Y Combinators, B Capital, Khosla Ventures, Bill & Melinda Gates Foundation, Draper Associates | Growth | Offers AtomNet, an AI driven platform to help users analyze molecular compounds and drug reaction and effectiveness. Atomwise also offers a screening service for clients to screen through chemical libraries to search for target compounds. Alternatively, their AI model is licensed for other organizations to adapt and introduce the model into their own drug discovery workflow. | Faster and more cost-efficient process of drug discovery | Machine learning AI model to predict molecular interaction between drugs and target proteins as well as screening through vast chemical libraries | The cost efficacy, accuracy rates, and faster speed of discovering drug compounds. | Mainly Business-To-Business model through partnerships, services, and licensing their AI technology to mainly biotech companies, pharmaceutical firms, and academic researchers. | Through their platform AtomNet, Atomwise uses neural networks to predict molecular binding to target proteins. This is done by processing through huge amounts of molecular data and chemical libraries to search and optimize for drug discovery. | Atomwise’s dual focus on technological innovation and strategic partnership has been the key to its success in carving its own space in the healthcare sector. Their ability to virtual screen enabled by their deep learning AI model analyzing molecular interactions between chemical compounds and target proteins is a unique approach to a problem: the slow speed and low efficacy of traditional methods in discovering drugs. Aside from their cutting edge technological methods, their business model that seeks business-scale partnerships in the use of their technology is only possible through their scalable AI model. | /content/drive/MyDrive/engin183profiles/Healthcare Profile/yidabin_5202061_91337930_Atomwise Business Profile.docx | Healthcare Profile | null | 45 | Series C | N/A (Private company) | null | null | null | 5 | 4 | 5 | 3 | 3 | 4 | 4 | 5 | 5 | 5 | 3 | 4 |
MyLime is an Italian blockchain startup specializing in digital product passports. The company uses blockchain technology to enhance product authentication, ownership tracking, and lifecycle transparency. Founded in 2018, MyLime is revolutionizing industries such as cycling and automotive by providing immutable records that certify the originality and history of products. | https://my-lime.com/ | Private | Authenticity Secured | Italy | 2,018 | null | Growth | MyLime provides blockchain-based digital passports for physical products, allowing customers to verify their authenticity and track their full ownership history. The company primarily serves the luxury automotive, cycling, and high-value goods industries. | Counterfeiting and lack of product traceability are major concerns in industries dealing with luxury goods. | MyLime leverages blockchain technology to create an immutable record of product history, ensuring authenticity and enhancing resale value. | Providing consumers and businesses with a secure, transparent method to authenticate product history through blockchain-powered digital passports. | MyLime operates on a subscription-based model, offering digital passport creation and verification services for brands and manufacturers. | The company employs blockchain technology to create tamper-proof digital records, ensuring authenticity and traceability of physical assets. | MyLime is an innovative blockchain company that provides digital passports to ensure product authenticity and ownership tracking. With strong applications in luxury and high-value goods markets, the company solves the challenge of counterfeiting by leveraging blockchain’s immutable ledger capabilities. Through partnerships with leading brands in cycling and automotive industries, MyLime is positioned as a key player in blockchain authentication solutions. As the demand for transparency grows in various industries, MyLime is set to expand its impact, making it an essential startup to watch in the blockchain space. | /content/drive/MyDrive/engin183profiles/blockchain - converted/alazzawianne_5627047_91209537_MyLime_BusinessProfile.docx | blockchain - converted | null | null | null | null | null | null | null | 4 | 3 | 5 | 4 | 3 | 4 | 4 | 5 | 4 | 5 | 4 | 5 |
Bridge.xyz is a financial technology company focused on simplifying global money movement through stablecoins, which are digital assets tied to traditional currencies like the U.S. dollar. Founded by former Square and Coinbase employees, Zach Abrams and Sean Yu, Bridge aims to provide businesses with a stablecoin payment system that integrates into their existing financial operations. This allows companies to move between crypto and traditional financial systems seamlessly, without managing blockchain complexities. In October 2024, Bridge was acquired by Stripe for $1.1 billion, marking Stripe's largest acquisition to date and highlighting its commitment to cryptocurrency integration. | www.bridge.xyz | Private | Make Money Move @ 3 x 10^8m/s | San Francisco, CA | 2,022 | Sequoia, Ribbit | For sale | Bridge offers a suite of APIs designed to simplify stablecoin transactions for businesses. Their Orchestration APIs help integrate stablecoins into existing financial processes, while their Issuance APIs allow companies to issue their own stablecoins. Bridge supports cross-chain transactions, fiat-to-crypto conversions, and provides virtual bank accounts for global transactions. | High fees, slow processing times, and inefficiences in traditional cross-border payment systems. | A blockchain-based platform utilizing stablecoins for instant, secure, and cost-effective global transfers. | Bridge delivers near-instant, low-cost international payments with enhanced security, making global transactions accessible and efficient for all. | Bridge operates on a transaction fee model, charging several basis points on each stablecoin-to-fiat or fiat-to-stablecoin transaction. The company's revenue model is scalable, with reported revenues reaching $15 million. | Bridge leverages blockchain technology, stablecoin protocols, and API-driven integrations to facilitate transactions. Its tech stack likely includes secure payment gateways, compliance software (e.g., KYC/AML tools), and partnerships with blockchain networks supporting major stablecoins like USDC or USDT. | Bridge.xyz emerged as a successful fintech startup by identifying and addressing a critical pain point in the cryptocurrency ecosystem: the difficulty of converting fiat currencies to stablecoins amid tightening banking regulations (e.g., Operation Choke Point). Its focused value proposition—offering a compliant, efficient on- and off-ramping solution—resonated with businesses and users, leading to its acquisition by Stripe for $1.1 billion in October 2024. The company’s success stems from strong leadership, a timely market entry, and a differentiated niche in a crowded fintech space, though its limited public profile and lack of disclosed funding suggest a lean, partnership-driven growth strategy. | /content/drive/MyDrive/engin183profiles/blockchain - converted/beheradebasish_5795058_91212155_Spring2025_Bridge.docx | blockchain - converted | 15 | 58 | null | N/A (private company) | N/A | null | N/A | 4 | 3 | 4 | 4 | 3 | 3 | 4 | 5 | 4 | 5 | 5 | 4 |
Sleeper is a popular sports betting company that focuses on enhancing the user experience in fantasy sports through combining social media with betting. They focus on creating a super fun and engaging experience for their users. | https://sleeper.com/ | Private | The Fantasy Sports You Know and Love, Reimagined | California | null | Greycroft, Next Ventures | null | List the offerings, including products and services being sold. | lack of interactive betting experience with friends | creating a social media platform where you can talk about games going on as well as place bets | unique combination of fantasy sports, sports betting, and social media | subscription, and premium use case, as well as sports betting | null | Sleeper’s success stems from its ability to combine social interaction with fantasy sports and betting, creating a unique platform that resonates well with sports enthusiasts. The company's focus on user engagement and community-building sets it apart in a crowded market. With strong backing from investors and a growing user base, Sleeper has the potential to continue expanding, especially in the competitive sports betting industry. However, it still faces challenges in scalability and competing with larger, more established players in the market. As someone who uses this platform, it definitely stands out compared to fellow competitors. Iff they are able to stay true to their brand, they have a bright future ahead. | /content/drive/MyDrive/engin183profiles/blockchain - converted/handeyash_5613058_91193559_ProfileFormat-Sleeper-YH.docx | blockchain - converted | null | 10 | Series B | N/A, private | N/A, private | N/A, private | N/A, private | 5 | 4 | 5 | 4 | 5 | 5 | 4 | 5 | 4 | 5 | 3 | 4 |
ChainSafe Systems is a research and development firm for blockchain that specializes in building infrastructure for Web3. It was founded in 2017 and is based in Toronto, Canada. ChainSafe has been a leader in Ethereum 2.0, Polkadot, and Filecoin ecosystems. ChainSafe excels at building open-source protocols and tools that enable interoperability as well as scalability among blockchain networks. | chainsafe.io | Private | null | Toronto, Canada | 2,017 | null | Growth | Lodestar: An open-source Ethereum 2.0 client written in TypeScript.
ChainBridge: A modular cross-chain bridge for Ethereum, Polkadot, and other networks to become interoperable.
Files.js is a JavaScript library designed to interact with the Filecoin network.
Web3.js Contributions: Active contributions to the Web3.js library, the backbone of Ethereum development. | Inability of various blockchain networks to interoperate. Complexity in dApp deployment and building. Scaling issues in existing blockchain platforms. | Their expertise in cross-chain interoperability and scalable infrastructure reduces the intricacy of blockchain development, enabling simpler and quicker adoption of Web3 technologies. | ChainSafe Systems provides cutting-edge, open-source blockchain technology that simplifies the development of decentralized applications (dApps) for developers. | Revenue Model: Grants, consultancy services, and business partnerships. | null | ChainSafe has become a significant firm in the blockchain development sector through the support of more than 50 researchers and engineers, and serving the needs of developers, enterprises, and blockchain enthusiasts. | /content/drive/MyDrive/engin183profiles/blockchain - converted/kraikriangsriamika_5794386_91211629_Untitled document (2).docx | blockchain - converted | null | 5 | null | N/A (Private company) | null | null | null | 5 | 3 | 4 | 4 | 4 | 5 | 4 | 5 | -1 | 5 | 4 | 5 |
Obol Collective is a blockchain startup dedicated to advancing decentralized staking infrastructure. The company is focused on developing Distributed Validator Technology (DVT), which enhances the security, resilience, and decentralization of Ethereum staking. By enabling multiple operators to co-run Ethereum validators, Obol Collective aims to mitigate the risks of validator downtime and centralization. The mission of the company is to build more secure and fault-tolerant staking services, ultimately supporting the growth and stability of the Ethereum ecosystem. | https://www.obol.tech | Private | Powering Decentralized Ethereum Staking | New York, United States | 2,021 | Pantera Capital, Coinbase Ventures, and ConsenSys | Growth | Obol Collective specializes in the development of Distributed Validator Technology (DVT). This technology allows multiple independent operators to collaborate in running an Ethereum validator node, significantly reducing the risks of single-point failures and improving the decentralization of the staking process. | Centralized staking services can lead to security risks and system vulnerabilities, undermining blockchain decentralization. | Obol Collective's DVT solution enhances validator resilience by distributing key responsibilities among multiple operators, ensuring higher uptime and security. | Obol Collective's provides a cutting-edge infrastructure solution that enables more secure, reliable, and decentralized Ethereum staking. | Obol Collective operates on a subscription-based model, offering services and software tools to staking providers and institutional investors. Additional revenue streams include consulting services for integrating DVT systems. Metrics focus on client acquisition, validator uptime rates, and subscription renewals. | Obol Collective leverages a sophisticated blockchain infrastructure, primarily focused on Ethereum's staking mechanism. The technology stack includes secure multiparty computation (SMPC), cryptographic key-sharing mechanisms, and open-source software protocols that ensure validator integrity and security. The company emphasizes privacy, redundancy, and fault-tolerance in all tech layers. | Obol Collective is a pioneering blockchain startup addressing critical challenges in Ethereum's staking infrastructure. With its Distributed Validator Technology (DVT), the company enhances the decentralization, security, and efficiency of validator nodes. By enabling multiple operators to manage a validator collaboratively, Obol Labs reduces centralization risks and system vulnerabilities. The company's subscription-based business model, combined with its innovative technological framework, positions it as a leader in decentralized staking solutions. Despite competition from networks like SSV and Rocket Pool, Obol Labs differentiates itself through its advanced cryptographic methods and strong focus on security and resilience. Obol Collective’s commitment to decentralization and blockchain integrity is driving its growth trajectory, making it a key player in the evolving Web3 ecosystem. | /content/drive/MyDrive/engin183profiles/blockchain - converted/leemichelle_5618088_91211913_obol collective.docx | blockchain - converted | null | 12 | Seed and Series A | N/A | N/A | N/A | N/A | 5 | 4 | 5 | 4 | 3 | 4 | 5 | 5 | 4 | 5 | 4 | 5 |
Hiro Systems is a blockchain technology company focused on building developer tools for Bitcoin layers, particularly Stacks. Founded in 2013, Hiro provides the infrastructure necessary for developers to create smart contracts, decentralized applications (dApps), and scalable solutions on Bitcoin. The company plays a crucial role in expanding Bitcoin's utility beyond a store of value, enabling new financial and digital use cases. Its mission is to unlock Bitcoin’s full potential by providing robust tools that empower developers to build decentralized applications directly on the Bitcoin network. The company aims to make Bitcoin a programmable blockchain while maintaining its security and decentralization. | https://www.hiro.so/ | Private | Hiro is a company for developers, built by developers. Everything they do enables developers to innovate and put the future back in the people’s hands. | Greater New York Area, East Coast, Northeastern US | 2,013 | Digital Currency Group, Rising Tide Fund, Hivemind, and CSC Upshot Ventures | Growth | Hirosystems offers a suite of developer tools to enhance the functionality of Bitcoin layers particularly Stacks. Their key product is Stacks.js, a JavaScript library for building applications on Stacks; Clarinet, a smart contract development and testing tool; Hiro Platform, a comprehensive web3 development platform; and Chainhook, a re-org aware indexing engine for bitcoin layers. Additionally, Hirosystems’ APIs provide developers with easy-to-use interfaces for accessing data related to Bitcoin, Ordinals, and Stacks. They can retrieve data and perform operations as the APIs offer structured and well-documented endpoints. Another tool provided by Hiro is Chainhooks which allows developers to create automated triggers on the Stacks and Bitcoin blockchains. This feature functions like webhooks but is specifically designed for blockchain applications. Lastly, they developed the Stacks Explorer which is an observability tool designed to help users, developers, miners, and investors understand the Stacks blockchains. It allows users to verify the finality and security of Stacks transactions by linking them to Bitcoin blocks. | Developers lack the tools to build smart contracts and scalable applications on Bitcoin. | Hirosystems provides developer tools like Stacks.js, Clarinet, Hiro Platform, and Chainhook to enable smart contracts and applications on Bitcoin layers. | Hiro empowers developers to build on Bitcoin by offering robust infrastructure and tooling which makes Bitcoin a viable platform for decentralized applications. | Hiro Systems operates on a B2B and developer-focused model providing developer tools, APIs, and infrastructure for building on Bitcoin and Stacks. Their revenue model includes open-source and developer adoption, enterprise and API monetization, channel and ecosystem partnerships. Their tools can be integrated into third-party applications and services which allows businesses to resell or build on top of Hiro’s infrastructure. Developers from over 50 countries have engaged with Hiro's tools, with significant participation from the Asia-Pacific region (34.5%) and North America (30.3%). | Hiro focuses on building essential development tools such as Stacks.js, Clarinet, Hiro Platform, Chainhook, and Stacks Explorer to support smart contract execution and application development on Bitcoin. | Hiro Systems has emerged as a pioneering force in blockchain development as it specializes in Bitcoin layers through its work on Stacks. Founded as Blockstack PBC, the company successfully pivoted to focus on developer tooling that enables smart contracts, decentralized applications (dApps), and Web3 functionalities on Bitcoin. This differentiation has made Hiro a key infrastructure provider, offering products such as Stacks.js, Clarinet, Chainhook, and Stacks Explorer, all of which simplify building on Bitcoin’s security layer. The company's success can be attributed to its strong leadership, particularly from Muneeb Ali, and its ability to navigate regulatory challenges while adapting to the shifting landscape of blockchain innovation. Hiro’s tools have significantly expanded Bitcoin’s utility, addressing a growing demand for Bitcoin DeFi, scalability solutions, and Layer 2 development. While Hiro’s financial sustainability is not as clear-cut—given its open-source model and reliance on ecosystem growth—its strategic funding rounds and ability to attract top-tier developers have solidified its place in the industry. Hiro’s continued success will depend on expanding its market reach beyond Stacks-native developers and increasing adoption of its tools in the broader blockchain community. By capitalizing on Bitcoin’s growing role in smart contracts and DeFi, HiroSystems is well-positioned to remain an essential player in blockchain infrastructure for many years to come. | /content/drive/MyDrive/engin183profiles/blockchain - converted/phamtara_5622363_91212289_HiroSystems.docx | blockchain - converted | 17.4 | 76 | Series A | N/A (Private company) | N/A | Negative (loss-making as of 2021) | N/A | 4 | 3 | 5 | 3 | 3 | 4 | 4 | 4 | 3 | 5 | 4 | 5 |
LI.FI, founded in 2021 and headquartered in Berlin, Germany, is a blockchain technology company specializing in cross-chain bridge and decentralized exchange (DEX) aggregation. The company provides a unified application programming interface (API) that enables seamless swapping, bridging, and zapping across major blockchains and protocols. By integrating various bridges and DEXs, LI.FI simplifies cross-chain transactions, enhancing the user experience in decentralized finance (DeFi). | https://li.fi/ | Private | One API to swap, bridge, and zap across all major blockchains and protocols. | Berlin, Germany | 2,021 | In April 2023, LI.FI raised $17.5 million in a funding round led by CoinFund and Superscrypt. | Growth | LI.FI offers a comprehensive platform that aggregates cross-chain bridges and DEXs, enabling users to perform on-chain swaps, cross-chain swaps, and a combination of both. The platform provides a widget for quick integration and a software development kit (SDK) for customized user experiences, facilitating seamless cross-chain transactions. | Navigating the fragmented blockchain ecosystem, where assets and liquidity are spread across multiple chains, poses challenges for users seeking efficient cross-chain transactions. | LI.FI's unified API aggregates various bridges and DEXs, simplifying the process of swapping and bridging assets across different blockchains, thereby enhancing interoperability and user experience. | LI.FI streamlines cross-chain transactions by providing a single integration point for developers and users, reducing complexity, saving development time, and offering access to a broad liquidity network. | LI.FI operates on a B2B model, offering its API, widget, and SDK to developers and businesses seeking to integrate cross-chain functionalities into their platforms. Revenue streams likely include service fees, subscription models, or partnerships, though specific details are not publicly disclosed. | The platform leverages blockchain technology to aggregate multiple cross-chain bridges and DEXs, providing a seamless interface for cross-chain swaps. It supports major blockchain protocols and utilizes smart contracts to facilitate secure and efficient transactions. | LI.FI has quickly established itself as a leading player in the cross-chain DeFi ecosystem by offering a powerful API that aggregates multiple blockchain bridges and DEXs. Its ability to streamline cross-chain transactions and provide a user-friendly, scalable solution has made it a go-to platform for developers and businesses alike. With strong leadership, significant funding, and a growing network of partners, LI.FI is well-positioned for continued growth and innovation. Its value proposition lies in reducing complexity and enhancing interoperability across blockchains, addressing a crucial need in the evolving DeFi space. | /content/drive/MyDrive/engin183profiles/blockchain - converted/primuthdavid_5719978_91211901_250310_Blockchain_Profile_David_Primuth.docx | blockchain - converted | null | 17.5 | Series A | N/A (Private company) | N/A | null | null | 5 | 4 | 5 | 4 | -1 | 4 | 4 | -1 | -1 | 5 | 4 | -1 |
Chainlink is a decentralized oracle network that enables smart contracts on blockchain platforms to securely interact with real-world data, APIs, and payment systems. It acts as a bridge between on-chain and off-chain data source, consequently ensuring that smart contracts use reliable, tamper-proof information. Chainlink aims to provide a means of universally interconnected smart contracts where no single centralized entity needs to be trusted for the secure automation of agreements. | https://chain.link/ | Private | Enabling the future of smart contracts | Grand Cayman, Cayman Islands | 2,017 | Sequoia Capital, Andreessen Horowitz, and other blockchain-focused venture capitalists | Growth | Chainlink provides decentralized oracle services that afford blockchain-oriented smart contracts with the security and decentralization necessary to access external data. Offering include, but are not limited to: Chainlink Data Feeds, which are reliable and decentralized oracles of prices for financial applications; Chainlink VRF (Verifiable Random Function), which provides a randomness solution for gaming and NFT applications; a decentralized automation solution for smart contracts termed Chainlink Keepers; and the Cross-Chain Interoperability Protocol (CCIP), which allows smooth communication among various blockchains. | Blockchain networks do not inherently connect to real-world data sources, APIs, or other traditional systems, and, consequently, smart contracts may be executed only on blockchain networks. | Chainlink provides decentralized oracle mechanisms that safely obtain and verify offchain data before making it available to smart contracts. | Chainlink guarantees reliable, secure, and an ever resistant to tampering access to real-world data, thus increasing the power of smart contracts almost in every business sector. | Chainlink works on a pay-as-you-use basis. In order to obtain and verify data, users pay a fee in LINK tokens to the node operators. It also collaborates with enterprises to offer blockchain-based solutions. | Chainlink is built on Ethereum and other blockchain networks, using a decentralized network of independent nodes to retrieve, verify, and deliver external data. The core technology stack includes smart contracts, cryptographic security, and consensus mechanisms to ensure data integrity. | Chainlink has emerged as the preeminent decentralized oracle provider, addressing a core issue in blockchain technology—namely, the insufficient access to trusted real-world data for smart contracts. Its group of independent node operators provides secure and tamper-proof delivery of actionable data, which is pivotal towards enhancing the functionality and trustworthiness of decentralized applications. Chainlink has made substantial investments to secure a lead in the oracle field based on endless partnerships with enterprise-grade clients, DeFi platforms, and blockchain ecosystems. By an ever-innovative range of implementations comprising genomic instance staking mechanisms and cross-chain interoperability solutions, Chainlink has great prospects as far as proliferation in the world of blockchain and DeFi is concerned. To crown it all, the early mover advantage, solid leadership, and sturdy tech stack will frame Chainlink as one of the major decentralized players in finance and automation. | /content/drive/MyDrive/engin183profiles/blockchain - converted/queanne_5780316_91206401_Spring2025_BusinessProfileFormat.docx | blockchain - converted | null | 32 | null | ~$8 billion (as of 2025) | Not publicly traded (Uses LINK token, currently valued at ~$18) | null | Not applicable (as Chainlink is a blockchain network, not a traditional corporation) | 5 | 4 | 5 | 4 | 3 | 4 | 5 | 5 | 4 | 5 | 5 | 5 |
Consensys is the leading blockchain and web3 software company. Since 2014, Consensys has been at the forefront of innovation, pioneering technological developments within the web3 ecosystem. Through their product suite, they have become a trusted collaborator for users, creators, and developers. Whether building a dapp, an NFT collection, a portfolio, or a better future, the instinct to build is universal. Their mission is to inspire and empower the builder in everyone by making web3 universally easy to use and develop on. | https://consensys.io/ | Private | START HERE. BUILD ANYTHING. | Fort Worth, TX | 2,014 | Balaji Srinivasan, BLN Capital, Dragonfly Capital, Factorial Funds, Hack VC, + More | Growth | Consensus is focused predominantly on Ethereum, and operates a suite of products including MetaMask and Infura. MetaMask is a cryptocurrency wallet that allows users to interact with Web3 applications easily. They have offerings for retail and institution alongside APIs that allow easy integration into other applications. | It is often hard to access Web 3 and build applications that work with it. | Consensus creates blockchain-based products that make it easy to adopt. | consensus.io provides developer tools and a main product of MetaMask - the everything wallet. | MetaMask Swap Fees (0.875%) - Fees to use the wallet. | Consensus.ai used many different languages (Node, Java, Python) and software frameworks to develop their application. | Consensys has been successful in establishing itself as a leader in the blockchain and Web3 space as it has provided unique tools that solve a clear challenge in a time where Web3 based applications are gaining popularity. Consensys’ tools help during the development process for decentralized applications and allow easy adoption of blockchain technology. One of the key factors that is supporting Consensys’ success is how the company has been able to adapt to the needs of the industry. Through products like MetaMask and Infura, Consensys has been able to find success in shaping Web3. | /content/drive/MyDrive/engin183profiles/blockchain - converted/rosmonmehreen_5722082_91211325_Spring2025_BusinessProfileFormat.docx | blockchain - converted | 1.5 | 11.5 | Series A | null | $43.79 | null | null | 4 | 5 | 4 | 3 | 4 | 3 | 3 | 5 | 4 | 4 | 4 | 3 |
Plasma is a rising blockchain company focused on stablecoin payments. Founded in 2023, Plasma is building a blockchain specifically designed to make stablecoin transactions more efficient. By combining the security of Bitcoin with Ethereum Virtual Machine compatibility, Plasma will solve a lot of the challenges stablecoins face on traditional blockchains, like high fees and slow transactions. The company’s goal is to provide a better experience for stablecoin users while increasing adoption across the financial ecosystem. | plasma.to | Private | Redefining how money moves | London, EN | 2,023 | Christian Angermayer, Ardoino, Bitfinex, Peter Thiel | Growth | Plasma’s main product is its blockchain platform built only for stablecoins. Plasma focuses on optimizing stablecoin transactions, unlike the more common blockchains (Ethereum, Tron) that support a wide range of applications but suffer from congestion and high fees. The platform supports zero-fee USD₮ (Tether) transfers and allows developers to deploy Ethereum-based smart contracts without modification. | Stablecoins are widely used, but the blockchains for them struggle with high fees, network congestion, and inefficiencies. Ethereum can be expensive and slow during peak usage. Tron is cheaper, but it’s been criticized for centralization risks. | Plasma solves these issues by offering a stablecoin blockchain with high throughput, low costs, and Bitcoin-based security, making it an ideal for stablecoin transactions. | Plasma provides a scalable, efficient, and secure blockchain built only for stablecoin transactions, which allows for zero-fee transfers and easy integration with current Ethereum-based applications. | Plasma operates on a platform-as-a-service model, offering blockchain infrastructure designed for stablecoins. Revenue likely comes from enterprise partnerships and integrations, however specific details are not publicly disclosed. | Plasma is a Bitcoin sidechain that is fully EVM-compatible. This means developers can migrate their Ethereum smart contracts without changing their code while benefiting from Bitcoin’s security. The blockchain is designed to support high-speed, low-cost stablecoin transactions, which makes it a strong alternative to current solutions. | Plasma is an exciting new blockchain company that is solving the issue of stablecoin transactions, one of the biggest issues in the current crypto space. By designing a blockchain optimized for stablecoins, Plasma gets rid of many of the inefficiencies seen on Ethereum, Tron, and other broader blockchains. With strong backing from industry leaders like Peter Thiel, Bitfinex, and Tether’s CEO, Plasma has both the funding and expertise to make a big impact. While still in its early stages, the company has a strong value proposition. The biggest challenge Plasma faces though is adoption, as current stablecoin issuers and users will have to migrate to this new blockchain. If Plasma can keep attracting major players in this space as it has been, it has the potential to be a game changer. | /content/drive/MyDrive/engin183profiles/blockchain - converted/sternwilliam_5656091_91195085_ENGIN183 HW4.docx | blockchain - converted | null | 24 | null | null | null | null | null | 4 | 4 | 4 | 3 | -1 | 3 | 4 | -1 | -1 | 4 | 4 | -1 |
K Health is a digital health company that leverages artificial intelligence to provide personalized primary care at an affordable cost. Founded in 2016, the company aims to make high-quality healthcare accessible through its AI-driven platform, which allows users to assess symptoms, consult with doctors, and receive treatment plans without needing an in-person visit. K Health's mission is to democratize healthcare by providing data-driven, real-time insights based on medical histories and past cases. | https://khealth.com/ | Private | Smarter Healthcare Without the Wait. | New York, NY, USA | 2,016 | Anthem, 14W, Mangrove Capital Partners, BoxGroup | Growth | K Health offers AI-driven healthcare services through its mobile and web platform, which includes symptom checking, primary care consultations, chronic condition management, and mental health support. The platform allows users to receive treatment and prescriptions from board-certified doctors without needing an in-person visit. | K Health addresses the inefficiencies and high costs of traditional healthcare by providing AI-powered medical assessments and direct access to doctors. This reduces the burden on emergency rooms and clinics while improving accessibility for users seeking affordable care. | K Health combines AI and real patient data to provide instant insights, virtual consultations, and affordable treatment plans without insurance requirements. | Affordable, data-driven healthcare with instant access to medical professionals, reducing wait times and unnecessary visits. | K Health operates on a subscription-based model, offering affordable healthcare plans starting at $9/month. It also provides pay-per-visit telehealth services and partners with insurance providers and employers. | K Health’s AI is built on a data set of millions of anonymized medical records, using machine learning to provide real-time symptom analysis. The platform integrates NLP (Natural Language Processing) to assess user input and improve diagnostic accuracy. | K Health is a fast-growing digital health company that combines AI-powered medical insights with virtual healthcare services to revolutionize primary care. By leveraging a vast database of medical records and advanced machine learning models, the company provides instant, affordable healthcare solutions without traditional insurance barriers. With strong leadership, a differentiated AI-driven approach, and a sustainable subscription-based model, K Health continues to expand its reach and redefine modern healthcare accessibility. Despite regulatory challenges and competition from traditional telemedicine providers, K Health’s ability to adapt and scale positions it as a major player in the evolving digital health industry. | /content/drive/MyDrive/engin183profiles/healthcare - converted/alazzawianne_5627047_91333757_K_Health_BusinessProfile.docx | healthcare - converted | 100 | 273.3 | null | null | null | null | null | 4 | 4 | 5 | 4 | 4 | 3 | 4 | 5 | 3 | 5 | 4 | 5 |
Viz.ai has developed a comprehensive AI platform that analyzes medical images, specifically CT scans, to detect signs of stroke. Their technology automatically alerts the appropriate medical team within minutes, bypassing traditional, time-consuming review processes. This rapid notification system enables faster diagnosis and treatment, reducing the window for brain damage and improving patient recovery. The company's solutions extend beyond stroke detection, encompassing other critical care areas and providing a scalable, integrated platform for healthcare systems. | null | Private | Supercharge your clinical data workflows | San Jose, CA | 2,016 | Oak HC/FT, DCM | Growth | Mendel.ai offers an AI platform that automates various stages of the clinical trial process, including feasibility assessments and post-trial pharmacovigilance. Their software transforms unstructured EMR data into structured data, enabling clinical experts to streamline global oncology research. | The complexity of unstructured clinical data makes it challenging for researchers to manage clinical trials. | Mendel.ai's AI platform processes unstructured clinical data, giving actionable insights that facilitate many stages of the clinical trial process. | By using AI to transform unstructured data into actionable intelligence, Mendel.ai is able to vastly accelerate clinical research. | Mendel.ai operates on a B2B model, offering its AI platform to healthcare institutions involved in clinical trials. | The company utilizes advanced AI algorithms to mimic physician-level cognitive abilities, processing unstructured EMR data into structured formats. | Viz.ai is a pioneering AI-powered stroke detection and care coordination platform. It utilizes advanced deep learning algorithms to analyze CT scans and identify potential strokes in real-time, alerting medical professionals and facilitating faster, more efficient patient care. The company's innovative technology addresses the critical issue of time-sensitive stroke treatment, significantly improving patient outcomes. Viz.ai's platform streamlines workflows, enhances communication between healthcare providers, and enables timely intervention, positioning it as a leader in AI-driven healthcare solutions. | /content/drive/MyDrive/engin183profiles/healthcare - converted/kraikriangsriamika_LATE_5794386_91346817_Healthcare tech business profile_Amika.docx | healthcare - converted | null | null | null | null | null | null | null | 4 | 3 | 4 | 4 | -1 | 4 | 3 | -1 | -1 | 5 | 3 | -1 |
FundamentalVR is a pioneering healthcare technology company specializing in virtual reality (VR) and haptic feedback systems for surgical training and medical education. Founded in 2012 and headquartered in London, UK, the company offers the Fundamental Surgery platform, which provides immersive, interactive simulations to enhance the skills of medical professionals. By integrating advanced VR with haptic technology, FundamentalVR enables users to experience realistic surgical procedures, improving competency and patient outcomes. | fundamentalvr.com | Private | Changing the Way Surgeons Learn and Perfect Their Skills | London, United Kingdom | 2,012 | EQT Life Science, Downing Ventures, Knights Templar Eye Foundation | Growth | FundamentalVR offers the Fundamental Surgery platform, scalable, and portable surgical training solution that combines VR immersion, haptic feedback, and AI-driven analytics. The platform supports a wide variety of surgical procedures, providing users with hyper-realistic simulations that replicate the tactile sensations of tissues and surgical instruments. Through the integration of their patented HapticVR® technology, trainees can practice surgical techniques with precision, enhancing muscle memory, accuracy, and overall competency. The platform also offers AI-powered analytics, providing personalized learning pathways, performance assessment, and progress tracking to enhance training efficiency and effectiveness. | Traditional surgical training is limited by accessibility, cost, and the availability of cadavers or live patients for practice. | FundamentalVR addresses these challenges by offering a risk-free, scalable training platform that uses VR and haptic feedback to simulate surgical procedures with high realism. | FundamentalVR delivers a highly immersive, scalable, and accessible surgical training solution, enabling practitioners to hone their skills without risk to patients. | FundamentalVR operates on a B2B model, partnering with medical device companies, pharmaceutical firms, medical schools, and healthcare institutions. Revenue streams include licensing fees, custom content development, subscription plans, and technical support services. Additionally, they collaborate with medical organizations to co-develop customized training modules for specialized surgical procedures, enhancing the platform’s credibility and market penetration. | The platform leverages HapticVR® technology, an advanced haptic feedback system designed to simulate the sensation of interacting with different tissues, organs, and surgical tools. This system integrates with VR hardware through dedicated haptic devices, providing a realistic and immersive training experience. It supports multiple VR headsets, including HTC Vive, Oculus Rift, and Meta Quest 2, ensuring compatibility and accessibility. The software utilizes AI-driven analytics to provide real-time performance feedback, track progress, and suggest improvements for enhanced skill development. | FundamentalVR has established itself as a leading innovator in the VR surgical training industry, offering a robust solution that combines haptic feedback and virtual reality to improve medical training. With strong leadership, consistent funding, and a differentiated product offering, the company has successfully created a scalable training solution that addresses key challenges in traditional surgical education. Although regulatory challenges remain, its partnerships with healthcare institutions and continuous innovation place FundamentalVR at the forefront of the medical VR training market. | /content/drive/MyDrive/engin183profiles/healthcare - converted/kulkarnidaksh_5794933_91338151_FundamentalVR business profile.docx | healthcare - converted | 12 | 39.6 | Series B | null | null | null | null | 4 | 3 | 4 | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 4 | 4 |
Developer of a database platform designed to organize the oncology information and make it useful for patients, physicians, life sciences and researchers. The company's database platform aggregates and transforms clinical and financial data from electronic medical records and billing systems, enabling Edward institutions to drive better patient experience, healthier practices and smarter research. | https://flatiron.com/ | Private | Flatiron is reimagining the infrastructure of cancer care. | 233 Spring Street, New York, NY, 10013, United States | 2,012 | Allen & Company, Amgen Ventures, Baillie Gifford, BoxGroup | null | Flatiron Health offers a variety of oncology-focused technology solutions aimed at improving cancer research, treatment, and care. Their core offerings include OncoEMR, an electronic medical records (EMR) platform designed for oncology practices, and Flatiron Assist, a clinical decision support tool that integrates real-world evidence to aid oncologists in selecting personalized treatment options. They also provide Flatiron Clinical Pipe, a data integration service which connects EMRs with research and clinical trial platforms, streamlining workflows for oncology professionals. Additionally, Flatiron’s real-world evidence (RWE) solutions leverage de-identified patient data to support pharmaceutical companies, researchers, and healthcare providers in drug development, regulatory decision-making, and personalized medicine. Their mission is to bridge the gap between care and research, making oncology data more accessible and actionable for better patient outcomes. | Flatiron Health addresses the challenge of fragmented and siloed oncology data by providing integrated technology solutions that bridge the gap between patient care and research. | Their solution is an oncology-focused technology platform that integrates electronic health records and real-world data such as OncoEMR, Flatiron Assist, and RWE analytics. | Flatiron bridges the gap between oncology care and research by enabling more personalized treatment and efficient clinical workflows using technology and science. | They operate on a subscription-based business model with elements of value added reselling and enterprise partnerships. Their primary revenue streams come from oncology clinics subscribing to OncoEMR and long-term contracts with life sciences and oncology practices. | Flatiron Health uses cloud-based data infrastructure, machine learning, and natural language processing to transform unstructured oncology data into actionable insights. Their technology stack includes Python, TensorFlow, and PyTorch for AI-driven data processing, along with AWS for scalable cloud storage and computing. They utilize FHIR Fast Healthcare Interoperability Resources and HL7 standards to integrate with electronic health records securely. Additionally, their real-world evidence solutions rely on big data analytics tools like Spark and SQL-based databases to extract meaningful trends that support clinical decision-making and drug development. | Flatiron Health became a success by revolutionizing oncology data through its real-world evidence (RWE) platform and OncoEMR, an electronic medical records system tailored specifically for cancer treatment. The company identified a critical gap in oncology care and developed solutions to bridge research and clinical practice. They leverage machine learning and large-scale data analytics, transforming how cancer data is collected and applied in clinical decision-making. This innovation has attracted major pharmaceutical companies, researchers, and regulatory agencies, making Flatiron a trusted partner in oncology drug development and treatment evaluation. Financially, Flatiron Health's growth was driven by a strong business model that combined SaaS-based revenue from OncoEMR subscriptions with high-value data licensing agreements with pharmaceutical firms. Backed by investors like Google Ventures, the company raised $313 million in funding before being acquired by Roche for $1.9 billion in 2018. This acquisition validated Flatiron’s impact and enabled the company to scale operations globally while maintaining independence under Roche's ownership. Despite its success, Flatiron has faced challenges in employee retention and culture post-acquisition, as well as limitations in expanding its platform beyond oncology. However, its regulatory alignment, technological edge, and strategic partnerships have solidified its role as a market leader in oncology data analytics. Flatiron continues to shape the future of medicine by enabling better treatment decisions and advancing cancer research. | /content/drive/MyDrive/engin183profiles/healthcare - converted/phamtara_5622363_91337846_Health Care Business Profile.docx | healthcare - converted | 358 | 313 | null | null | null | null | null | 4 | 4 | 5 | 4 | 3 | 3 | 4 | 5 | 5 | 5 | 5 | 4 |
CarePredict is a young company in the health technology sector whose goal is enriching senior care with proactive and data-based insights. CarePredict uses wearables and machine learning to track the daily habits of older adults residing in senior living environments and at home. Since its inception in 2013, CarePredict's mission is to provide caregivers, families, and health professionals with timely information that aims to help avoid preventable health-related issues such as falls, malnutrition, depression, and hospitalization. Their technology is equipped to manage personal and preventive care to not only lead to better health outcomes for seniors but also foster overall independence. | https://www.carepredict.com | Private | Smarter Care. Better Life. | Plantation, Florida, USA | 2,013 | Secured over $50M in funding from Secocha Ventures, Las Olas Venture Capital, and others | Growth | CarePredict has a wearable smart device called Tempo that obtains behavior and activity data on eating, bathing, walking, sleeping, and social interaction. This data is then analyzed to find patterns and anomalies that are likely to indicate health issues. The CarePredict platform is used in senior living facilities and homes to facilitate early interventions and continuous improvement in care delivery systems. Major feature services include predictive fall detection, reporting on health trends, real-time alerts to caregivers, and integration with third-party medical systems. | Older adults frequently suffer health declines that may go unnoticed until it is too late to prevent avoidable hospitalizations, injuries, and loss of independence. Traditional monitoring is more reactionary than proactive. | CarePredict promotes proactive senior care through the use of wearable technologies and AI to pick up subtle changes in behavior that may signal health deterioration before it becomes acute. | By using AI-powered behavioral tracking to identify early health risks and improve outcomes, we offer proactive, personalized senior care. | CarePredict is a subscription-based platform serving both B2B and B2C partnerships. Facilities and families subscribe monthly for access to the analytics dashboard, wearable device service, and platform. They also work collaboratively with healthcare providers and insurance companies under a value-based care model. While company revenue metrics are not publicly shared, it's experiencing rapid growth, particularly in the assisted living space. | CarePredict utilizes a combination of wearable sensors, BLE (Bluetooth Low Energy) based indoor position tracking, and machine learning algorithms to capture activity patterns daily. CarePredict's technology stack consists of the following components: Hardware: Custom wearable device (Tempo) Software: Cloud-based analytics dashboard AI/ML: Behavioral pattern recognition, anomaly detection, etc. Integrations: EHR (Electronic Health Records) systems, etc. | CarePredict has emerged as one of the most innovative healthcare startups focused on elder care. With its AI-driven wearable device and behavioral analytics, it addresses a pressing issue in healthcare: the need for proactive, continuous monitoring of seniors. Its value lies in personalized care enabled through technology, offering caregivers the ability to prevent critical incidents before they occur. The combination of strong leadership, unique product differentiation, and a clear market need have made CarePredict a standout player in the growing eldercare tech space. Despite challenges such as scaling B2C adoption and market awareness, the company has demonstrated adaptability and resilience. It continues to gain recognition through awards and growing partnerships with senior care facilities and insurance providers. | /content/drive/MyDrive/engin183profiles/healthcare - converted/queanne_LATE_5780316_91339866_Spring2025_BusinessProfileFormat-1.docx | healthcare - converted | null | 50 | Series B | null | null | null | null | 5 | 4 | 5 | 4 | 3 | 4 | 4 | 5 | 4 | 5 | 4 | 5 |
Rula is a company in the behavioral healthcare space, on a mission to make mental health care work for everyone. The majority of Americans give up before they get the help they need due to a system that feels broken and overwhelming. Rula is changing that. By connecting individuals with licensed mental health professionals who specialize in their unique needs, Rula ensures that care is not only accessible but also personalized and affordable. Through a network of dedicated providers and a commitment to making quality care available when and where people need it, Rula is building the future of mental health care. | https://www.rula.com/about-us/ | Private | Our mission is to make mental healthcare work for everyone. | LA, CA | 2,019 | Hedosophia, Blue Venture Fund, Company K Partners, Four Rivers Group, and GS Futures | Growth | 1 paragraph to list the offerings, including products and services being sold. | Access to mental healthcare is not easily accessible. | Providing a simple solution to make mental health care, therapy, and resources available to all through an online platform. | In your own words | null | 1 paragraph to describe tech being leveraged, summary of tech stack. | Rula's success in the health tech space is due to its ability to simplify and improve access to high-quality mental health care in a system that has been challenging to utilize. Rula created a simplified platform that removes obstacles after realizing that millions of Americans have had difficulty finding the correct mental health providers and that many give up before getting treatment. Rula guarantees that clients may get care that is quick, reasonably priced, and customized to meet their individual needs by collaborating with major insurance networks and providing a wide, well screened provider network. Rula is also different because it is dedicated to providing care that is based on data and outcomes. Its tech based method gives clients and providers more power by giving them tools for scheduling, billing, and tracking progress. These tools make administrative tasks easier and keep the focus on the health of the patients. Rula has grown quickly and become a trusted leader in mental health care thanks to its compassionate care, smart insurance partnerships, and efficient operations. Rula's plan has not only helped clients and therapists, but it has also filled in long-standing gaps in the mental health care system, which has helped it continue to grow and be successful. | /content/drive/MyDrive/engin183profiles/healthcare - converted/rosmonmehreen_5722082_91336882_HealthTech Profile.docx | healthcare - converted | 675 | 83 | over 4 rounds | 1.25 billion | null | null | null | 5 | 4 | 3 | 4 | 3 | 4 | 1 | 3 | 3 | 4 | 1 | 3 |
AItrics is a pioneering healthcare technology company that transforms patient care through artificial intelligence. With a mission to vitalize healthcare with AI, AItrics develops solutions that enhance clinical decision-making, streamline medical workflows, and ultimately save lives. The company is committed to driving innovation in the healthcare industry by leveraging advanced machine learning and predictive analytics to support medical professionals in delivering more efficient and effective care. | https://aitrics.com | Private | AI solution by doctors for doctors. | Seoul, South Korea | 2,016 | Premier Partners, BNH Investment, BSK Investment, JX Partners, HB Investment, HRZ, Ulmer Investments, RISE | Growth | AITRICS-VC: AItrics’s flagship product, AITRICS-VC, is designed to predict critical patient conditions using electronic medical record (EMR) data. Approved by the Ministry of Food and Drug Safety and recognized as an Innovative Medical Device, AITRICS-VC provides early detection of life-threatening events, such as sepsis, cardiac arrest, and unexpected ICU transfers. By analyzing up to 19 key data points—including vital signs, blood test results, Glasgow Coma Scale (GCS), and patient age—the software generates predictive scores that help medical professionals take timely, life-saving actions. SEPS Score predicts sepsis risk within four hours, MAES Score anticipates major adverse events within six hours, and MOR Score assesses mortality risk in ICUs. AITRICS-VC integrates into hospital networks, providing real-time monitoring and AI-powered decision support to improve patient outcomes and enhance hospital operational efficiency. V.Doc: An AI-powered medical examination solution designed to streamline the entire patient journey, from pre-visit assessments to post-care management. V.Doc generates optimized medical interview questions based on a patient’s symptoms, compiling responses into a comprehensive health report to assist doctors in making faster, more informed diagnoses. After consultations, V.Doc Care provides personalized post-care guidelines to ensure continuous patient monitoring. | Delayed detection of life-threatening conditions such as sepsis, cardiac arrest and sudden ICU transfers, in traditional hospital monitoring methods, resulting in patient deterioration that could’ve been prevented. | AI-powered predictive analytics platform which processes real-time electronic medical record (EMR) data to detect early warning signs of critical health conditions. By analyzing up to 19 key clinical data points, the software generates predictive scores for sepsis, major adverse events, and mortality, giving doctors the time and insights needed to act preemptively. | AItrics helps healthcare professionals detect early signs of patient deterioration with greater accuracy, reducing administrative burden and providing personalized, data-driven care. This enables faster diagnoses, better resource management, and improved patient experiences, while lowering mortality rates, minimizing ICU admissions. | AItrics uses a B2B subscription-based model, providing its AI-driven healthcare solutions to hospitals and medical institutions. Clients subscribe to AItrics' services, such as AITRICS-VC, to integrate predictive analytics into their clinical workflows. | AITRICS-VC uses machine learning models to analyze EMR data, including vital signs, blood test results, and Glasgow Coma Scale, to predict patient risks like sepsis, ICU transfers, and cardiac arrest. V.Doc incorporates natural language processing (NLP) and speech-to-text (STT) technology to generate medical interview questions and transcribe real-time consultations, assisting in diagnosis and post-care management while reducing administrative burden. Both solutions leverage cloud infrastructure for scalability and secure data storage. Additionally, AItrics has 2 registered patents in the ‘computing; calculating’ category and has registered 7 trademarks, the most notable being ‘Scientific and electric apparatus and instruments’. | AItrics’ success is largely driven by its differentiation, specifically through its patents and unique technologies. The company’s AITRICS-VC (Vital Care) is the only AI solution in Korea capable of predicting sepsis, giving it a competitive edge in the healthcare AI market. This exclusivity, combined with a strong intellectual property portfolio and industry certifications, provides both legal protection and authentication, reinforcing its credibility and innovation. AItrics’ timing has also been a critical factor in its success. With the growing need transformation within the healthcare system and for AI-driven healthcare solutions, AItrics is well-positioned to meet this demand. While the regulatory landscape presents challenges, the company has managed to navigate these hurdles effectively, which is why its timing was rated a 4—reflecting both its strong market opportunity and the potential risks involved in scaling within a regulated industry. Leadership is another key success factor. AItrics’ products are developed by doctors, ensuring that the company deeply understands healthcare professionals' pain points, giving it an authoritative voice in the market. Additionally, the company’s ability to pivot and adapt to changing market needs, such as developing V.Doc in response to evolving consumer expectations and AI advancements, showcases its resilience and capacity to innovate. | /content/drive/MyDrive/engin183profiles/healthcare - converted/serafinnina_5660605_91324246_Spring2025_BusinessProfileF-AItrics.docx | healthcare - converted | 7.8 | 29.9 | Series B | null | null | null | null | 5 | 4 | 5 | 4 | 3 | 4 | 5 | 5 | 5 | 5 | 4 | 5 |
Mendel.ai is a health tech company focused on solving challenges at each stage of the clinical trial process. Their AI platform is designed to mimic physician-level cognitive abilities, transforming unstructured electronic medical records (EMR) data and clinical literature into comprehensive information. This enables clinical experts to improve global oncology research by automating various aspects of clinical trials. | mendel.ai | Private | Supercharge your clinical data workflows | San Jose, CA | 2,016 | Oak HC/FT, DCM | Growth | Mendel.ai offers an AI platform that automates various stages of the clinical trial process, including feasibility assessments and post-trial pharmacovigilance. Their software transforms unstructured EMR data into structured data, enabling clinical experts to streamline global oncology research. | The complexity of unstructured clinical data makes it challenging for researchers to manage clinical trials. | Mendel.ai's AI platform processes unstructured clinical data, giving actionable insights that facilitate many stages of the clinical trial process. | By using AI to transform unstructured data into actionable intelligence, Mendel.ai is able to vastly accelerate clinical research. | Mendel.ai operates on a B2B model, offering its AI platform to healthcare institutions involved in clinical trials. | The company utilizes advanced AI algorithms to mimic physician-level cognitive abilities, processing unstructured EMR data into structured formats. | Mendel.ai has made itself a key player in the healthcare technology sector by addressing the complexities of unstructured clinical data in the clinical trial process. Through its AI-driven platform, the company offers solutions that enhance the efficiency of clinical research particularly in oncology. With a strong leadership team and backing from reputable investors, Mendel.ai continues to grow in the healthcare industry. | /content/drive/MyDrive/engin183profiles/healthcare - converted/sternwilliam_5656091_91314011_ENGIN183_Profile_HealthcareAI.docx | healthcare - converted | null | null | null | null | null | null | null | 4 | 3 | -1 | 4 | -1 | 4 | 3 | -1 | -1 | 5 | 3 | -1 |
Clarius is a healthcare tech company which produces handheld wireless ultrasound scanners to generate high resolution and affordable imaging for accurate diagnosing and visualizing anatomy to guide procedural treatment, compared to traditional ultrasound machines which aren’t cost-effective. Through utilizing complex algorithms in artificial intelligence, Clarius aims to assist clinicians of various specialties generate nuanced insights regarding the diagnosis in a precise and timely manner, while adhering to safety protocols and affordability. Ultimately, it hopes to improve and democratize accessibility to ultrasound imaging tools for healthcare professionals to use by being compatible with smartphones and tablets. | clarius.com | Private | An image you can trust. | Vancouver, BC, Canada | 2,014 | Nimbus Synergies, Listwin Ventures, Nicola Wealth Private Capital, etc. | Hypergrowth | There are various types of handheld wireless ultrasound scanners catered for various health specialties such as women’s health and sports medicine. Clarius HD3 emphasizes overall image quality by utilizing piezoelectric arrays for in-depth scanning and reduced noise as well as producing consistent imaging over time. Included with a Clarius membership, Clarius Cloud allows to store unlimited imaging regarding patient exams, mark annotations, generate reports, and share and export those reports, making them accessible anywhere with an internet connection. Additionally, they also offer educational webinars and worldwide events demonstrating the usage of such scanners. | Traditional ultrasound scanners are expensive and aren’t compact and approximately 25 million healthcare professionals don’t have access to such scanners. | Produce compact handheld wireless ultrasound scanners through AI, which generate high resolution imaging through smartphones and tablets, making it accessible, cost-effective, and user-friendly. | As opposed to traditional, expensive ultrasound machines, Clarius produces AI-powered high-resolution, compatible ultrasound imaging providing clinicians with nuanced diagnosis to combat expensive healthcare costs and improve overall patient outcome. | Ultrasound scanners are sold as a one-time cost, implementing a fixed price model. Through Clarius membership paid monthly or annually which provides advanced imaging and cloud storage, the subscription model is being implemented, emphasizing customer retention. VAR and Channel is also being implemented as Clarius partners with medical distributors and resellers to expand its offerings and overall revenue. | Clarius utilizes sophisticated algorithms in AI to recognize and distinguish various anatomical structures in the high resolution ultrasound images. By integrating machine learning algorithms as well, diagnostic capabilities are enhanced and automated through ultrasound imaging. Through cloud integration in Clarius Cloud, ultrasound images are securely stored and shared through generating reports. By being compatible with iOS and Android, mobile app development is being implemented and by offering the products are wireless, the products are compatible with Bluetooth and internet connection. | The success of Clarius can be attributed to its unique innovation of creating handheld wireless ultrasound scanners which produced high-resolution imaging by leveraging AI/ML and was more accessible and affordable of use to healthcare professionals of various specialties, as a way to combat the complexities of traditional ultrasound machines which were expensive and not compact. In turn, this improved patient diagnosis as it produced the images in a efficient and timely manner. By partnering with various medical distributors and resellers worldwide, Clarius continues to expand its offerings revolutionizing the healthcare industry as there are currently over 10,000+ users in 60 countries. | /content/drive/MyDrive/engin183profiles/healthcare - converted/venkatesanharshita_LATE_5732585_91342853_Healthcare_profile.docx | healthcare - converted | 30 | 3.4 | Series C | N/A | N/A | N/A | N/A | 4 | 4 | 5 | 5 | 5 | 3 | 5 | 5 | 3 | 5 | 5 | 5 |
Biobot Analytics develops cutting-edge technology to transform sewers into public health observatories. Wastewater contains valuable information about the health of communities. We collect it. We analyze it. We tell you how to leverage it to make your city better. | https://biobot.io/# | Private | Harness the power of wastewater intelligence | Boston | 2,017 | Y-combinator | Growth | Biobot Analytics provides insighful intelligence from data gathered by examining wastewater. By analyzing sewage, they can detect pathogens like COVID-19, flu, RSV, and mpox, helping communities identify potential outbreaks early. They also track high-risk substances such as fentanyl, cocaine, and methamphetamine to provide data on drug use trends. Their platform offers real-time insights, allowing governments and organizations to make informed decisions and allocate resources more effectively to support public health initiatives. | Disease Epidemics | Examining sewge to capture early information and potential outbreaks | Biobot Analytics' value proposition lies in its ability to transform wastewater into actionable public health data. | They form contracts with government agencies, they have subscription fees, and they provide consulting services. Moreover, they secured a Y-combinator venture capital investment. | I’d imagine they would use cloud infra and data analytics tools to do the analysis, but I’m not familiar with analyzing healthcare stuff, nor can I find much on their tech stack. | Honestly, I believe a big part of their success was their differentiation and the fact that they completed Y-Combinator’s accelerator program. Their value proposition is something that not only does the healthcare industry highly value, but also government agencies, which can play a big part in success. | /content/drive/MyDrive/engin183profiles/healthcare - converted/yudavid_LATE_5621219_91342934_Healthcare AI.docx | healthcare - converted | null | null | null | null | null | null | null | 1 | 2 | 5 | 1 | 1 | 3 | 4 | 3 | 5 | 5 | 5 | 5 |
Subsets and Splits